Disabling Pansclerotic Morphea of Childhood

Mendelian MONDO:0957497 Pathograph 24 Show in embeddings browser Localized scleroderma Autoinflammatory disease Autosomal dominant disease

A rare, severe systemic inflammatory and fibrosing disorder at the most severe end of the juvenile localized scleroderma (morphea) spectrum, with onset usually in early childhood. Rapidly progressive sclerosis extends circumferentially from the dermis through subcutaneous fat and fascia into muscle and bone, producing joint contractures, musculoskeletal atrophy, articular ankylosis and immobility. Poor wound healing with chronic skin and mucosal ulceration is characteristic, and long-standing ulcers carry a risk of cutaneous squamous cell carcinoma. Unlike systemic sclerosis, internal organ fibrosis is typically absent and scleroderma-associated autoantibodies are usually not detected. Systemic features in genetically defined cases include cytopenias, hypogammaglobulinemia, raised inflammatory markers and recurrent infections. Heterozygous germline gain-of-function missense variants in the SH2 domain of STAT4 were identified in three unrelated families with autosomal dominant or de novo disease; they produce constitutive STAT4 phosphorylation and an interleukin-6-driven autoinflammatory loop in dermal fibroblasts, and the JAK1/2 inhibitor ruxolitinib improved disease in treated patients. The disease is otherwise refractory to conventional immunosuppression and carries high morbidity and mortality from sepsis, gangrene, restrictive pulmonary disease and squamous cell carcinoma.

Ask OpenScientist

Ask a research question about Disabling Pansclerotic Morphea of Childhood. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
1
Inheritance
6
Pathophys.
29
Phenotypes
24
Pathograph
1
Genes
9
Medical Actions
12
References
1
Deep Research
🏷

Classifications

Harrison's Part
IMMUNE RHEUMATOLOGIC DERMATOLOGY GENETICS ENVIRONMENT DISEASE
🔗

Mappings

ICD-10-CM
ICD10CM:L94.0 Localized scleroderma [morphea]
skos:broadMatch dismech
ICD-10-CM has no code for disabling pansclerotic morphea or for STAT4-related disease; L94.0 covers all localized scleroderma (morphea) and is broader than this entry.
👪

Inheritance

1
Autosomal dominant HP:0000006
Monoallelic STAT4 gain-of-function variants were inherited in an autosomal dominant pattern or arose de novo; p.His623Tyr has recurred de novo in an unrelated Chinese child. Expressivity is variable: in two of three families a first-degree relative carried milder disease (oral ulceration, mild skin disease or early-onset progressive swan-neck deformities of the hands), which the authors suggest may reflect genetic modifiers.
Autosomal dominant inheritance
Show evidence (3 references)
PMID:37256972 SUPPORT Human Clinical
"We evaluated four patients from three unrelated families with an autosomal dominant pattern of inheritance of DPM."
Documents autosomal dominant transmission across the three families.
PMID:37256972 SUPPORT Human Clinical
"Our identification of novel, autosomal dominantly inherited or de novo variants in STAT4 appears to be the first description of a gain-of-function variant in this gene and the first genetic link for DPM."
States that the variants were either dominantly inherited or de novo.
PMID:37256972 SUPPORT Human Clinical
"additional genetic modifiers of disease severity could exist, which may account for the presence of a parent with milder disease in two of the three families"
Records variable expressivity, with mildly affected parents in two of the three families.
⚙

Pathophysiology

6
STAT4 SH2-Domain Gain-of-Function Signaling
Mechanism confidence: Established
Heterozygous SH2-domain missense variants make STAT4 constitutively active. Variant STAT4 drives an IL6 promoter reporter in the absence of stimulation, shows raised phosphorylated STAT4 at baseline, and after interferon-alpha stimulation keeps phosphorylated STAT4 elevated for longer than wild type. Variant protein accumulates in the nucleus, and patient dermal fibroblasts show phosphorylated STAT4 at baseline. Persistent phosphorylation in the absence of new phosphorylation suggests that mutant dimers are more stable than wild-type dimers.
STAT4 hgnc:11365 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves STAT4 (hgnc:11365). hgnc:11365 is a gene from the HUGO Gene Nomenclature Committee.
Genetic context STAT4 hgnc:11365 HUGO Gene Nomenclature Committee (hgnc) Relation: this genetic context concerns this gene This genetic context concerns STAT4 (hgnc:11365). hgnc:11365 is a gene from the HUGO Gene Nomenclature Committee. variant_origin: GERMLINE zygosity: HETEROZYGOUS functional_impact_category: GAIN_OF_FUNCTION
Monoallelic SH2-domain missense variants (H623Y, A635V, A650D), inherited dominantly or arising de novo.
STAT4 signaling GO:0007259 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased STAT4 signaling, annotated with cell surface receptor signaling pathway via JAK-STAT (GO:0007259). GO:0007259 is a biological process from the Gene Ontology. ↑ INCREASED
STAT4 transcription activator activity GO:0001228 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves STAT4 transcription activator activity, annotated with DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228), qualified as gain of function. GO:0001228 is a molecular function from the Gene Ontology. ⇑ GAIN OF FUNCTION
Downstream
Fibroblast Interleukin-6 Autoinflammatory Loop Variant STAT4 increases transcription from the IL6 promoter, a STAT4 target, and patient fibroblasts secrete excess interleukin-6.
Lymphocyte Inflammatory Transcriptional Program STAT4 is highly expressed in NK and T cells, and in these cells ruxolitinib reduced the inferred activity of IFNG, IFNA, TNF, IL6 and STAT1. The specific STAT4-dependent steps in lymphocytes are not resolved; interleukin-12-induced STAT4 phosphorylation in patient T cells was not increased.
Neutropenia Neutropenia resolved on JAK inhibition, which ties it to JAK-STAT signalling; which cell population carries the effect is not established.
Anemia Anemia decreased on JAK inhibition; the mechanism is not established.
Thrombocytopenia Thrombocytopenia stabilized on JAK inhibition; the mechanism is not established.
Pulmonary arterial hypertension Pulmonary hypertension improved in one patient after ruxolitinib was started; the vascular mechanism is not characterized.
Show evidence (3 references)
PMID:37256972 SUPPORT In Vitro
"In unstimulated cells with variant STAT4, pSTAT4 levels were higher than those in cells transfected with control STAT4"
Baseline hyperphosphorylation of variant STAT4 in a STAT1/STAT4-deficient cell line.
PMID:37256972 SUPPORT In Vitro
"the increased levels of pSTAT4 were comparatively durable in cells containing variant STAT4"
Prolonged phosphorylation after interferon-alpha stimulation, consistent with resistance to signal termination.
PMID:37256972 SUPPORT In Vitro
"pSTAT4 was evident at baseline in primary skin fibroblasts from patients but not in fibroblasts from healthy donors despite these cells having similar levels of STAT4 expression"
Shows constitutive STAT4 activation in patient-derived primary dermal fibroblasts.
Fibroblast Interleukin-6 Autoinflammatory Loop
Mechanism confidence: Established
Unstimulated dermal fibroblasts from patients secrete about 12 times as much interleukin-6 as fibroblasts from healthy donors. Variant-transfected cells also express more interleukin-6 and SOCS genes. Interleukin-6 itself reproduces the patient fibroblast defects in healthy-donor fibroblasts, which supports a self-sustaining autoinflammatory loop in the stroma. Anti-interleukin-6 treatment produced only a modest improvement in vitro, whereas upstream JAK inhibition with ruxolitinib reduced interleukin-6 secretion.
dermal fibroblast CL:0002551 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves dermal fibroblast, annotated with fibroblast of dermis (CL:0002551). CL:0002551 is a cell type from the Cell Ontology.
interleukin-6 production GO:0032635 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased interleukin-6 production (GO:0032635). GO:0032635 is a biological process from the Gene Ontology. ↑ INCREASED interleukin-6-mediated signaling GO:0070102 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased interleukin-6-mediated signaling, annotated with interleukin-6-mediated signaling pathway (GO:0070102). GO:0070102 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Impaired Fibroblast Wound Repair Pulsing healthy-donor fibroblasts with recombinant interleukin-6 reproduced the patient phenotype: reduced migration, failed scratch closure, reduced contraction and enlarged cells.
Show evidence (2 references)
PMID:37256972 SUPPORT In Vitro
"unstimulated skin fibroblasts from patients secreted 12 times as much interleukin-6 as those from healthy donors"
Quantifies interleukin-6 hypersecretion by patient dermal fibroblasts.
PMID:37256972 SUPPORT In Vitro
"In vitro treatment with anti-interleukin-6 led to a modest improvement in fibroblast function but suggested that upstream targeting of this molecular pathway may be required to inhibit autoinflammation"
Interleukin-6 blockade alone only partly reverses the fibroblast phenotype.
Impaired Fibroblast Wound Repair
Mechanism confidence: Established
Patient dermal fibroblasts migrate slowly and fail to close a scratch wound, contract a collagen matrix poorly after TGF-beta stimulation, show disorganized F-actin with enlarged cell size, and secrete less procollagen alpha-1 while fibronectin secretion is unchanged. Ruxolitinib restored the rate of scratch closure in patient fibroblasts. This cellular defect is the proposed basis of the poor wound healing and chronic ulceration of DPM.
dermal fibroblast CL:0002551 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves dermal fibroblast, annotated with fibroblast of dermis (CL:0002551). CL:0002551 is a cell type from the Cell Ontology.
fibroblast migration GO:0010761 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased fibroblast migration (GO:0010761). GO:0010761 is a biological process from the Gene Ontology. ↓ DECREASED wound healing GO:0042060 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased wound healing (GO:0042060). GO:0042060 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Poor wound healing The authors relate the fibroblast defects to the clinical failure of wound healing; the in vitro to in vivo step is inferential.
Skin ulcer Defective fibroblast repair is proposed to underlie the chronic, nonhealing skin ulcers.
Oral ulcer Mucosal ulceration is an early and consistent sign and resolved on ruxolitinib; the link to the fibroblast repair defect is inferred.
Show evidence (2 references)
PMID:37256972 SUPPORT In Vitro
"Skin fibroblasts from a patient with STAT4 A635V did not migrate as rapidly as fibroblasts from healthy donors and ultimately did not close the induced gap"
Patient fibroblasts fail a scratch wound-closure assay.
PMID:37256972 SUPPORT In Vitro
"Patient-derived fibroblasts had less contractility than fibroblasts from healthy donors"
Defective collagen-matrix contraction, another component of wound repair.
Lymphocyte Inflammatory Transcriptional Program
Mechanism confidence: Provisional
Single-cell RNA sequencing of patient peripheral-blood cells showed an immunodysregulatory profile in NK cells and T cells, which express STAT4 highly. Ruxolitinib reduced the inferred activity of inflammatory regulators including IFNG, IFNA, TNF, IL6 and STAT1. Th1 skewing was not observed, but T-cell subsets showed evidence of exhaustion. Skin biopsies show a subepidermal inflammatory infiltrate composed mostly of CD3-positive T cells. How STAT4 gain of function produces the systemic cytopenias and hypogammaglobulinemia is not established.
natural killer cell CL:0000623 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves natural killer cell (CL:0000623). CL:0000623 is a cell type from the Cell Ontology. T cell CL:0000084 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves T cell (CL:0000084). CL:0000084 is a cell type from the Cell Ontology.
inflammatory response GO:0006954 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased inflammatory response (GO:0006954). GO:0006954 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Acute phase response Inflammatory markers normalized when the inflammatory program was suppressed by ruxolitinib.
Progressive Deep Tissue Sclerosis Lesional skin combines a T-cell-rich inflammatory infiltrate with alpha smooth-muscle actin staining indicative of fibrosis. How the STAT4-driven inflammation produces deep sclerosis is not resolved: patient fibroblasts in vitro secreted less, not more, procollagen.
Show evidence (2 references)
PMID:37256972 SUPPORT Human Clinical
"ruxolitinib treatment decreased the activity of genes such as IFNG, IFNA, TNF, IL6 and STAT1, which control multiple inflammatory pathways"
JAK inhibition reverses an inflammatory transcriptional program in patient NK and T cells.
PMID:37256972 SUPPORT Human Clinical
"whereas interleukin-12-induced phosphorylation of STAT4 in patient peripheral-blood T cells, typical of type 1 helper T (Th1) cell skewing, was not affected, although T-cell subsets had evidence for exhaustion"
Interleukin-12-induced STAT4 phosphorylation in patient T cells was normal, while T-cell subsets showed exhaustion, so the lymphocyte defect is not simple Th1 hyperactivation.
Type II Interferon-Driven Fibroblast-Dendritic Cell Crosstalk
Mechanism confidence: Provisional
Single-cell and spatial transcriptomics of lesional skin from one patient with pansclerotic morphea showed a dominant type II interferon response, with T cells as the main IFN-gamma source. IFN-gamma-responsive CXCL9+ fibroblasts lay near the T cells and were related to profibrotic, TGF-beta-responsive COL8A1+ myofibroblasts, with cDC2B dendritic cells as a predicted communication hub. TGF-beta and IFN-gamma synergistically induced CXCL9 and CXCL10 in fibroblasts, and serum CXCL9 tracked disease activity in a separate pansclerotic morphea cohort. The patient's STAT4 genotype was not reported, so this node is a tissue-level model of pansclerotic morphea that has not been tied to the STAT4 lesion.
dermal fibroblast CL:0002551 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves dermal fibroblast, annotated with fibroblast of dermis (CL:0002551). CL:0002551 is a cell type from the Cell Ontology. myofibroblast CL:0000186 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves myofibroblast, annotated with myofibroblast cell (CL:0000186). CL:0000186 is a cell type from the Cell Ontology. T cell CL:0000084 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves T cell (CL:0000084). CL:0000084 is a cell type from the Cell Ontology. cDC2B conventional dendritic cell CL:0000990 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves cDC2B conventional dendritic cell, annotated with conventional dendritic cell (CL:0000990). CL:0000990 is a cell type from the Cell Ontology.
response to IFN-gamma GO:0034341 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased response to IFN-gamma, annotated with response to type II interferon (GO:0034341). GO:0034341 is a biological process from the Gene Ontology. ↑ INCREASED myofibroblast differentiation GO:0036446 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased myofibroblast differentiation (GO:0036446). GO:0036446 is a biological process from the Gene Ontology. ↑ INCREASED
dermis UBERON:0002067 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in dermis (UBERON:0002067). UBERON:0002067 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Progressive Deep Tissue Sclerosis CXCL9+ inflammatory fibroblasts are related to COL8A1+ myofibroblasts with a TGF-beta response and high extracellular-matrix gene expression.
Show evidence (3 references)
PMID:37471168 SUPPORT Human Clinical
"Fibrotic skin was characterized by prominent type II IFN response, accompanied by infiltrating myeloid cells, B cells, and T cells, which were the main IFN-γ source."
Patient skin transcriptomics establish a type II interferon-dominated lesional milieu.
PMID:37471168 SUPPORT In Vitro
"In vitro, TGF-β and IFN-γ synergistically increased CXCL9 and CXCL10 expression, contributing to the perpetuation of IFN-γ responses."
Cultured dermal fibroblast experiment showing a feed-forward chemokine loop.
PMID:37471168 SUPPORT Human Clinical
"We found that serum levels of CXCL9 were positively associated with higher LoSAI scores"
An IFN-gamma-inducible chemokine tracks clinical disease activity in a nine-patient cohort.
Progressive Deep Tissue Sclerosis
Mechanism confidence: Established
Rapidly progressive sclerosis involves all layers of the skin and extends circumferentially into subcutaneous fat, fascia, muscle and bone, and can involve mucous membranes. Imaging shows deep-tissue inflammation and sclerosis from subcutis to muscle. Fibrosis of internal organs is typically absent, distinguishing DPM from systemic sclerosis. Deep sclerosis causes contractures, musculoskeletal atrophy and articular ankylosis.
extracellular matrix organization GO:0030198 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased extracellular matrix organization (GO:0030198). GO:0030198 is a biological process from the Gene Ontology. ↑ INCREASED
dermis UBERON:0002067 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in dermis (UBERON:0002067). UBERON:0002067 is an anatomical location from the Uberon multi-species anatomy ontology. subcutaneous fat UBERON:0002190 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in subcutaneous fat, annotated with subcutaneous adipose tissue (UBERON:0002190). UBERON:0002190 is an anatomical location from the Uberon multi-species anatomy ontology. fascia UBERON:0008982 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in fascia (UBERON:0008982). UBERON:0008982 is an anatomical location from the Uberon multi-species anatomy ontology. skeletal muscle UBERON:0001134 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in skeletal muscle, annotated with skeletal muscle tissue (UBERON:0001134). UBERON:0001134 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Morphea
Joint contracture
Skeletal muscle atrophy
Ankylosis
Skin ulcer Deep sclerosis with musculoskeletal atrophy is described as resulting in cutaneous ulceration; the intermediate steps are not specified.
Show evidence (3 references)
PMID:37256972 SUPPORT Human Clinical
"Musculoskeletal imaging showed deep-tissue inflammation and sclerosis of several levels from subcutis to muscle, findings consistent with DPM."
Imaging of the STAT4-variant patients documents sclerosis from subcutis to muscle.
PMID:39520387 SUPPORT REVIEW SYNTHESIS Human Clinical
"DPM is characterized by rapid sclerosis with circumferential involvement that frequently extends to the fascia, muscle and bone."
Literature-wide synthesis of the depth and pattern of sclerosis.
PMID:39520387 SUPPORT REVIEW SYNTHESIS Human Clinical
"Internal organ fibrosis is typically absent."
Records the absence of visceral fibrosis that separates DPM from systemic sclerosis.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Disabling Pansclerotic Morphea of Childhood Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

29
Blood 7
Neutropenia Decreased total neutrophil count HP:0001875 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Mild neutropenia, annotated with Decreased total neutrophil count (HP:0001875). HP:0001875 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37256972 SUPPORT Human Clinical
"Laboratory evaluations showed mild neutropenia and lymphopenia, especially with respect to CD4+ T cells, and elevated serum inflammatory markers in three of the four patients."
Neutropenia in three of four STAT4-variant patients.
Lymphopenia Decreased total lymphocyte count HP:0001888 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Lymphopenia, predominantly CD4+ T cells, annotated with Decreased total lymphocyte count (HP:0001888). HP:0001888 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37256972 SUPPORT Human Clinical
"Laboratory evaluations showed mild neutropenia and lymphopenia, especially with respect to CD4+ T cells, and elevated serum inflammatory markers in three of the four patients."
Lymphopenia, especially of CD4+ T cells, in three of four patients.
Anemia HP:0001903 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Anemia (HP:0001903). HP:0001903 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37256972 SUPPORT Human Clinical
"His neutropenia resolved, inflammatory markers normalized, anemia decreased, and thrombocytopenia stabilized"
Anemia, with thrombocytopenia and neutropenia, in a STAT4-variant patient, improving on ruxolitinib.
Thrombocytopenia HP:0001873 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Thrombocytopenia (HP:0001873). HP:0001873 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37256972 SUPPORT Human Clinical
"His neutropenia resolved, inflammatory markers normalized, anemia decreased, and thrombocytopenia stabilized"
Thrombocytopenia in a STAT4-variant patient, stabilized on ruxolitinib.
Decreased circulating IgG concentration HP:0004315 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypogammaglobulinemia (low IgG), annotated with Decreased circulating IgG concentration (HP:0004315). HP:0004315 is a phenotype from the Human Phenotype Ontology.
Sequelae: Recurrent infections
Show evidence (2 references)
PMID:37256972 SUPPORT Human Clinical
"serum levels of immunoglobulin classes IgG and IgA were reduced in three of the four patients"
Reduced IgG in three of four patients.
PMID:7356347 REFUTE Human Clinical
"Laboratory data were characterized by a polyclonal elevation of gamma-globulin level and by peripheral eosinophilia."
The original clinical series reported raised rather than reduced gamma-globulin, so hypogammaglobulinemia may be specific to the STAT4-defined cases rather than to all clinically defined DPM.
Decreased circulating IgA concentration HP:0002720 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is IgA deficiency, annotated with Decreased circulating IgA concentration (HP:0002720). HP:0002720 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:37256972 SUPPORT Human Clinical
"serum levels of immunoglobulin classes IgG and IgA were reduced in three of the four patients"
Reduced IgA in three of four patients; IgA deficiency persisted on ruxolitinib in one.
PMID:37256972 SUPPORT Human Clinical
"normal IgG and IgM levels, with persistent IgA deficiency"
IgA deficiency persisted after IgG normalized on treatment.
Eosinophilia Increased total eosinophil count HP:0001880 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Peripheral eosinophilia, annotated with Increased total eosinophil count (HP:0001880). HP:0001880 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:7356347 SUPPORT Human Clinical
"Laboratory data were characterized by a polyclonal elevation of gamma-globulin level and by peripheral eosinophilia."
Peripheral eosinophilia in the 14-child series.
Cardiovascular 2
Pulmonary arterial hypertension HP:0002092 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pulmonary hypertension, annotated with Pulmonary arterial hypertension (HP:0002092). HP:0002092 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37256972 SUPPORT Human Clinical
"Pulmonary nodules and infiltrates, pulmonary and portal hypertension, rapid-onset blindness (glaucoma and cataracts resulting in surgery), and sensorineural hearing loss were less frequent findings."
Pulmonary hypertension among the less frequent findings.
Portal hypertension HP:0001409 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Portal hypertension (HP:0001409). HP:0001409 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37256972 SUPPORT Human Clinical
"Pulmonary nodules and infiltrates, pulmonary and portal hypertension, rapid-onset blindness (glaucoma and cataracts resulting in surgery), and sensorineural hearing loss were less frequent findings."
Portal hypertension among the less frequent findings.
Ear 1
Sensorineural hearing impairment HP:0000407 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Sensorineural hearing loss, annotated with Sensorineural hearing impairment (HP:0000407). HP:0000407 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37256972 SUPPORT Human Clinical
"Pulmonary nodules and infiltrates, pulmonary and portal hypertension, rapid-onset blindness (glaucoma and cataracts resulting in surgery), and sensorineural hearing loss were less frequent findings."
Sensorineural hearing loss among the less frequent findings.
Eye 2
Glaucoma HP:0000501 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Glaucoma (HP:0000501). HP:0000501 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37256972 SUPPORT Human Clinical
"Pulmonary nodules and infiltrates, pulmonary and portal hypertension, rapid-onset blindness (glaucoma and cataracts resulting in surgery), and sensorineural hearing loss were less frequent findings."
Glaucoma among the less frequent findings.
Cataract HP:0000518 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cataract (HP:0000518). HP:0000518 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37256972 SUPPORT Human Clinical
"Pulmonary nodules and infiltrates, pulmonary and portal hypertension, rapid-onset blindness (glaucoma and cataracts resulting in surgery), and sensorineural hearing loss were less frequent findings."
Cataract among the less frequent findings.
Head and Neck 1
Oral ulcer HP:0000155 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Oral mucosal ulceration, annotated with Oral ulcer (HP:0000155). HP:0000155 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:37256972 SUPPORT Human Clinical
"Two of the families had first-degree relatives with oral ulcerations, mild skin disease, or early-onset progressive hand swan-neck deformities"
Oral ulceration occurs in affected families, including mildly affected relatives.
PMID:37256972 SUPPORT Human Clinical
"After 11 months of therapy, the rash and oral ulcers had largely resolved."
Documents oral ulcers in a treated patient and their response to ruxolitinib.
Immune 3
Panniculitis HP:0012490 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hyaline panniculitis, annotated with Panniculitis (HP:0012490). HP:0012490 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:7356347 SUPPORT Human Clinical
"Lymphocytic inflammation and hyaline pannicultitis were observed on biopsy specimens in some cases."
Biopsy finding in the original 14-child series (the source spells it "pannicultitis").
Recurrent infections HP:0002719 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Recurrent infections (HP:0002719). HP:0002719 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37256972 SUPPORT Human Clinical
"Two patients also had recurrent infections, and squamous-cell carcinoma had developed in one patient."
Recurrent infections in two of four STAT4-variant patients.
Sepsis HP:0100806 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Sepsis (HP:0100806). HP:0100806 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:18048875 SUPPORT Human Clinical
"Four patients died because of complications of the disease such as sepsis or gangrene."
Sepsis as a fatal complication.
Integument 4
Morphea OBLIGATE HP:0012344 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pansclerotic morphea, annotated with Morphea (HP:0012344). HP:0012344 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:37256972 SUPPORT Human Clinical
"All four patients had had disease onset before 5 years of age, with signs of mucosal ulcerations and skin sclerosis"
Skin sclerosis was present in all four STAT4-variant patients.
PMID:29455178 SUPPORT Human Clinical
"There was marked thickening of collagen bundles in the lower reticular dermis."
Histology of a DPM skin lesion.
Poor wound healing HP:0001058 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Poor wound healing (HP:0001058). HP:0001058 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37256972 SUPPORT BACKGROUND Human Clinical
"Disabling pansclerotic morphea (DPM) is a rare systemic inflammatory disorder, characterized by poor wound healing, fibrosis, cytopenias, hypogammaglobulinemia, and squamous-cell carcinoma."
Poor wound healing is a defining feature in the description of the disease.
Skin ulcer HP:0200042 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Chronic nonhealing skin ulcer, annotated with Skin ulcer (HP:0200042). HP:0200042 is a phenotype from the Human Phenotype Ontology.
Sequelae: Squamous cell carcinoma of the skin
Show evidence (2 references)
PMID:18048875 SUPPORT Human Clinical
"Five patients suffered from chronic nonhealing leg ulcers (17%), but ulcers were present on other parts of the body (upper limbs, trunk, head) as well (n = 6)."
Frequency and distribution of chronic ulcers across 30 published and new DPMC patients.
PMID:37256972 SUPPORT Human Clinical
"three of the patients had spreading of their rash and worsening ulcerations, with rapid development of contractures, muscular atrophy, and impairments in mobility"
Progressive ulceration in STAT4-variant patients despite immunosuppression.
Squamous cell carcinoma of the skin HP:0006739 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Ulcer-associated cutaneous squamous cell carcinoma, annotated with Squamous cell carcinoma of the skin (HP:0006739). HP:0006739 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:18048875 SUPPORT Human Clinical
"Two patients developed a squamous cell carcinoma at the age of 16 years and 19 years, respectively (6.7%)."
SCC frequency and age at onset in a combined case series.
PMID:28543434 SUPPORT Human Clinical
"We describe a young man with long-standing DPMC and SCC with lung metastasis."
SCC in DPMC can metastasize.
Metabolism 1
Acute phase response HP:0033331 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Elevated serum inflammatory markers, annotated with Acute phase response (HP:0033331). HP:0033331 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37256972 SUPPORT Human Clinical
"Laboratory evaluations showed mild neutropenia and lymphopenia, especially with respect to CD4+ T cells, and elevated serum inflammatory markers in three of the four patients."
Raised inflammatory markers in three of four patients.
Musculoskeletal 4
Joint contracture FREQUENT HP:0034392 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Joint contracture (HP:0034392). HP:0034392 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:18048875 SUPPORT Human Clinical
"The majority of patients had an aggressive course with deep sclerotic lesions leading to joint contractures and immobility."
Contractures in most of 30 DPMC patients.
PMID:17143989 SUPPORT Human Clinical
"rapid progression of deep cutaneous fibrosis extending into the muscle fascia with disabling joint contractures of the hips, knees, ankles, and fingers"
Distribution of contractures in a single case.
Skeletal muscle atrophy HP:0003202 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Musculoskeletal atrophy, annotated with Skeletal muscle atrophy (HP:0003202). HP:0003202 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37256972 SUPPORT Human Clinical
"three of the patients had spreading of their rash and worsening ulcerations, with rapid development of contractures, muscular atrophy, and impairments in mobility"
Muscular atrophy developed in three of four STAT4-variant patients.
Ankylosis HP:0031013 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Articular ankylosis, annotated with Ankylosis (HP:0031013). HP:0031013 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37256972 SUPPORT BACKGROUND Human Clinical
"rapidly progressive deep fibrosis involving the mucous membranes, dermis, subcutaneous fat, fascia, muscles, and bone, leading to contractures, musculoskeletal atrophy, and articular ankylosis"
Articular ankylosis as an end-stage consequence of deep fibrosis.
Arthritis HP:0001369 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Polyarthritis with joint swelling, annotated with Arthritis (HP:0001369). HP:0001369 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:37256972 SUPPORT Human Clinical
"the first symptom that developed in Patient 2 was polyarthritis"
Polyarthritis as a presenting feature.
PMID:37256972 SUPPORT Human Clinical
"an autoinflammatory disease with joint swelling at 3 years of age, hand contractures at 7 years of age, and progressive skin ulcerations beginning at 8 years of age"
Joint swelling preceded contractures and ulceration in another patient.
Respiratory 3
Restrictive ventilatory defect HP:0002091 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Restrictive pulmonary disease, annotated with Restrictive ventilatory defect (HP:0002091). HP:0002091 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37256972 SUPPORT BACKGROUND Human Clinical
"DPM is associated with high morbidity and mortality due to squamous-cell carcinoma, restrictive pulmonary disease, sepsis, and gangrene"
Names restrictive pulmonary disease as a cause of morbidity and mortality in DPM.
Pulmonary nodule HP:0033608 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pulmonary nodule (HP:0033608). HP:0033608 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37256972 SUPPORT Human Clinical
"Pulmonary nodules and infiltrates, pulmonary and portal hypertension, rapid-onset blindness (glaucoma and cataracts resulting in surgery), and sensorineural hearing loss were less frequent findings."
Pulmonary nodules among the less frequent findings.
Pulmonary infiltrates HP:0002113 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pulmonary infiltrates (HP:0002113). HP:0002113 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37256972 SUPPORT Human Clinical
"Pulmonary nodules and infiltrates, pulmonary and portal hypertension, rapid-onset blindness (glaucoma and cataracts resulting in surgery), and sensorineural hearing loss were less frequent findings."
Pulmonary infiltrates among the less frequent findings.
Constitutional 1
Gangrene HP:0100758 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Gangrene (HP:0100758). HP:0100758 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:18048875 SUPPORT Human Clinical
"Four patients died because of complications of the disease such as sepsis or gangrene."
Gangrene as a fatal complication.
🧬

Genetic Associations

1
STAT4
Gene: STAT4 hgnc:11365 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is STAT4 (hgnc:11365). hgnc:11365 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (4 references)
PMID:37256972 SUPPORT Human Clinical
"Genome sequencing revealed three novel heterozygous missense gain-of-function variants in STAT4."
Identifies heterozygous STAT4 missense variants in all three affected kindreds.
PMID:37256972 SUPPORT Human Clinical
"Each occurs in the region of STAT4 that encodes the SH2 domain"
Locates all three variants in the SH2-domain-encoding region.
PMID:37256972 SUPPORT Human Clinical
"Gain-of-function variants in STAT4 caused DPM in the families that we studied."
The authors' causal conclusion for the gene-disease relationship.
+ 1 more reference
💊

Medical Actions

9
Ruxolitinib
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: ruxolitinib CHEBI:66919 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses ruxolitinib (CHEBI:66919). CHEBI:66919 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Oral JAK1/2 inhibitor. In patient fibroblasts it reduced interleukin-6 secretion, phosphorylated STAT4 and its nuclear localization, and restored scratch-wound closure. In two treated STAT4-variant patients it cleared rash and oral ulcers, normalized inflammatory markers, resolved neutropenia and improved pulmonary hypertension without reported adverse events. JAK inhibitors are not approved for DPM; the authors propose this approach for refractory disease.
Mechanism Target:
STAT4 SH2-Domain Gain-of-Function Signaling — Blocks the JAK kinases upstream of STAT4 phosphorylation.
Show evidence (1 reference)
PMID:37256972 SUPPORT In Vitro
"Ruxolitinib treatment also reduced the total amount of pSTAT4 and its nuclear localization in unstimulated U3A cells and patient fibroblasts"
Ruxolitinib lowers constitutive STAT4 activation.
Fibroblast Interleukin-6 Autoinflammatory Loop
Show evidence (1 reference)
PMID:37256972 SUPPORT In Vitro
"Ruxolitinib significantly reduced interleukin-6 secretion at concentrations achievable in serum"
Ruxolitinib suppresses fibroblast interleukin-6 hypersecretion.
Impaired Fibroblast Wound Repair
Show evidence (1 reference)
PMID:37256972 SUPPORT In Vitro
"ruxolitinib enhanced the rate of scratch closure of patient fibroblasts to one nearly identical to that of fibroblasts from healthy donors"
Ruxolitinib restores fibroblast wound closure in vitro.
Lymphocyte Inflammatory Transcriptional Program
Show evidence (1 reference)
PMID:37256972 SUPPORT Human Clinical
"ruxolitinib treatment decreased the activity of genes such as IFNG, IFNA, TNF, IL6 and STAT1, which control multiple inflammatory pathways"
Ruxolitinib reverses the lymphocyte inflammatory program in a treated patient.
Show evidence (3 references)
PMID:37256972 SUPPORT Human Clinical
"Inhibition of Janus kinase (JAK)-STAT signaling with ruxolitinib led to improvement in the hyperinflammatory fibroblast phenotype in vitro and resolution of inflammatory markers and clinical symptoms in treated patients, without adverse effects."
Clinical and in vitro response to ruxolitinib in STAT4-variant DPM.
PMID:37256972 SUPPORT Human Clinical
"Patient 2 has since begun therapy with ruxolitinib, with improvement in his pulmonary hypertension."
Improvement in pulmonary hypertension on ruxolitinib.
PMID:40518164 SUPPORT Human Clinical
"经激素及芦可替尼（早5.0 mg+晚2.5 mg）治疗后明显缓解"
Chinese-language abstract: after glucocorticoids and ruxolitinib (5.0 mg morning, 2.5 mg evening) the STAT4 p.His623Tyr patient improved markedly, an independent report of response to JAK inhibition.
Methotrexate and Systemic Corticosteroids
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: methotrexate CHEBI:44185 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses methotrexate (CHEBI:44185). CHEBI:44185 is a therapeutic agent from Chemical Entities of Biological Interest. corticosteroid CHEBI:50858 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses corticosteroid (CHEBI:50858). CHEBI:50858 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
The most commonly used regimen in reported cases, often combined with ultraviolet A phototherapy. Responses are limited; DPM is generally refractory to glucocorticoids and conventional immunosuppression.
Show evidence (2 references)
PMID:30838436 SUPPORT REVIEW SYNTHESIS Human Clinical
"Methotrexate and corticosteroids have been the most commonly utilized."
Methotrexate and corticosteroids are the most frequently used agents across 37 reported cases.
PMID:37256972 REFUTE BACKGROUND Human Clinical
"DPM is refractory to therapy, including systemic glucocorticoids, immunosuppression, and autologous stem-cell transplantation."
Conventional immunosuppression generally fails to halt progression.
Mycophenolate Mofetil
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: mycophenolate mofetil CHEBI:8764 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses mycophenolate mofetil (CHEBI:8764). CHEBI:8764 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Anecdotally effective; subjective improvement was reported with prednisolone and mycophenolate mofetil.
Show evidence (1 reference)
PMID:30838436 SUPPORT REVIEW SYNTHESIS Human Clinical
"MMF has been anecdotally effective."
Anecdotal benefit across reported cases.
Tocilizumab
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: tocilizumab NCIT:C84217 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses tocilizumab (NCIT:C84217). NCIT:C84217 is a therapeutic agent from the NCI Thesaurus.
Platform: Monoclonal antibody
Anti-interleukin-6 receptor monoclonal antibody, used off label in refractory pansclerotic morphea. In two children it reduced disease activity and halted progression. Neither child was genotyped.
Mechanism Target:
Fibroblast Interleukin-6 Autoinflammatory Loop — Blocks the interleukin-6 receptor; in STAT4-variant fibroblasts, interleukin-6 blockade alone gave only modest in vitro improvement.
Show evidence (1 reference)
PMID:28980909 SUPPORT Human Clinical
"We describe the first two cases of children with PM refractory to different immunosuppressive agents in which the use of TCZ reduced disease activity and stopped disease progression."
Case-level response to interleukin-6 receptor blockade in refractory childhood pansclerotic morphea.
Ultraviolet A Phototherapy
Action: PhototherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Phototherapy (NCIT:C15301). NCIT:C15301 is a clinical intervention from the NCI Thesaurus. NCIT:C15301
Platform: Other
Phototherapy, often with methotrexate and corticosteroids, has been reported to reduce skin thickness and plaque stiffness.
Show evidence (1 reference)
PMID:30838436 SUPPORT REVIEW SYNTHESIS Human Clinical
"Phototherapy has been documented to be reducing skin thickness and stiffness of plaques."
Reported benefit of phototherapy on skin thickness.
Bosentan
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: bosentan CHEBI:51450 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses bosentan (CHEBI:51450). CHEBI:51450 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Dual endothelin receptor antagonist used for refractory ischemic ulcers; improvement of ulcers, skin thickness and joint mobility was reported in a single child.
Show evidence (1 reference)
PMID:17143989 SUPPORT Human Clinical
"limb ulcers improved, with resolution of the widespread sclerotic skin lesions"
Single-case response of ulcers and sclerosis to bosentan.
Sildenafil with Acellular Matrix Wound Dressing
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: sildenafil CHEBI:9139 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses sildenafil (CHEBI:9139). CHEBI:9139 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Sildenafil combined with repeated application of porcine small-intestinal submucosa acellular matrix markedly improved chronic leg ulcers in reported cases.
Show evidence (1 reference)
PMID:18048875 SUPPORT Human Clinical
"We report on marked improvement of chronic leg ulcers by a combination of sildenafil 3 x 20 mg/day and repeated application of a porcine small intestinal submucosal acellular matrix."
Reported ulcer response to combined sildenafil and acellular matrix.
Intravenous Immunoglobulin Replacement
Action: Intravenous immunoglobulin therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Intravenous immunoglobulin therapy (NCIT:C121331). NCIT:C121331 is a clinical intervention from the NCI Thesaurus. Ontology label: Intravenous Immunoglobulin Therapy NCIT:C121331
Platform: Protein replacement
Used for hypogammaglobulinemia with low IgG in a STAT4-variant patient.
Show evidence (1 reference)
PMID:37256972 SUPPORT Human Clinical
"He continues to receive intravenous immunoglobulin (2 g per kilogram of body weight) for IgG levels below 1000 mg per deciliter"
Immunoglobulin replacement for low IgG.
Physical Therapy
Action: Physical therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Physical therapy (NCIT:C15302). NCIT:C15302 is a clinical intervention from the NCI Thesaurus. Ontology label: Physical Therapy NCIT:C15302
Platform: Behavioral / lifestyle
The mainstay of non-pharmacological management, aimed at maintaining function and muscle strength and preventing flexion contractures.
Show evidence (1 reference)
PMID:29455178 SUPPORT BACKGROUND Human Clinical
"Physical therapy remains the mainstay of non-pharmacological management and may aid in maintaining functional ability, muscle strength and prevention of flexion contractures."
Role of physical therapy in preserving function.
🔬

Diagnosis

3
Skin biopsy (PRESENT)
The clinical diagnosis of DPM rests on skin histology showing deep sclerosis with an inflammatory infiltrate; in the STAT4 families the diagnosis had been made this way before genetic testing.
Show evidence (1 reference)
PMID:37256972 SUPPORT Human Clinical
"both had received diagnoses of DPM by means of skin biopsy"
Skin biopsy established the clinical diagnosis in the index patients.
Musculoskeletal imaging (PRESENT)
Imaging shows how deep the inflammation and sclerosis extend, from subcutis to muscle, which is what separates the pansclerotic form from superficial morphea.
Show evidence (1 reference)
PMID:37256972 SUPPORT Human Clinical
"Musculoskeletal imaging showed deep-tissue inflammation and sclerosis of several levels from subcutis to muscle, findings consistent with DPM."
Imaging documented the depth of tissue involvement characteristic of DPM.
Genome sequencing for STAT4 variants (PRESENT)
Sequencing identifies the heterozygous STAT4 gain-of-function variant that defines the genetic form and points to JAK inhibition as a treatment.
Show evidence (1 reference)
PMID:37256972 SUPPORT Human Clinical
"Genome sequencing revealed three novel heterozygous missense gain-of-function variants in STAT4."
Genome sequencing identified the causal STAT4 variants.
📊

Prevalence

2
Worldwide
Cases In Literature Not yet documented
A 2025 systematic literature review identified 86 published patients in 52 reports up to December 2023. These are clinically defined cases; most were reported before the STAT4 association and were not genotyped.
Show evidence (1 reference)
PMID:39520387 SUPPORT REVIEW SYNTHESIS Human Clinical
"We identified 52 reports comprising 86 patients published up to December 2023."
Cumulative published case count from a systematic literature review; a case tally, not a population prevalence estimate.
Not specified (pansclerotic morphea, all ages)
Unknown ≤0.01 per 100,000 <1 in 1,000,000
The single-cell study of pansclerotic morphea states a prevalence of less than 1 per 10,000,000, citing earlier sources; the measure type and population are not given. The figure concerns pansclerotic morphea generally rather than the genetically defined childhood form, and is an upper bound (rate_high records the 0.01 ceiling).
Show evidence (1 reference)
PMID:37471168 SUPPORT BACKGROUND Human Clinical
"an extremely rare, difficult-to-treat disease, with a prevalence of less than 1 per 10,000,000"
Introduction sentence restating a prevalence ceiling from cited literature; the paper's own data are transcriptomic, not epidemiological.
{ }

Source YAML

click to show 
name: Disabling Pansclerotic Morphea of Childhood
creation_date: "2026-10-01T20:21:47Z"
category: Mendelian
synonyms:
- disabling pansclerotic morphea
- DPM
- DPMC
- disabling pansclerotic morphoea of childhood
- pansclerotic morphea
description: >-
  A rare, severe systemic inflammatory and fibrosing disorder at the most severe end of the juvenile
  localized scleroderma (morphea) spectrum, with onset usually in early childhood. Rapidly progressive
  sclerosis extends circumferentially from the dermis through subcutaneous fat and fascia into muscle and
  bone, producing joint contractures, musculoskeletal atrophy, articular ankylosis and immobility. Poor
  wound healing with chronic skin and mucosal ulceration is characteristic, and long-standing ulcers carry
  a risk of cutaneous squamous cell carcinoma. Unlike systemic sclerosis, internal organ fibrosis is
  typically absent and scleroderma-associated autoantibodies are usually not detected. Systemic features in
  genetically defined cases include cytopenias, hypogammaglobulinemia, raised inflammatory markers and
  recurrent infections. Heterozygous germline gain-of-function missense variants in the SH2 domain of STAT4
  were identified in three unrelated families with autosomal dominant or de novo disease; they produce
  constitutive STAT4 phosphorylation and an interleukin-6-driven autoinflammatory loop in dermal
  fibroblasts, and the JAK1/2 inhibitor ruxolitinib improved disease in treated patients. The disease is
  otherwise refractory to conventional immunosuppression and carries high morbidity and mortality from
  sepsis, gangrene, restrictive pulmonary disease and squamous cell carcinoma.
disease_term:
  preferred_term: disabling pansclerotic morphea of childhood
  term:
    id: MONDO:0957497
    label: disabling pansclerotic morphea of childhood
parents:
- Localized scleroderma
- Autoinflammatory disease
- Autosomal dominant disease
classifications:
  harrisons_chapter:
  - classification_value: IMMUNE_RHEUMATOLOGIC
  - classification_value: DERMATOLOGY
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: NOT_YET_DOCUMENTED
  notes: >-
    A 2025 systematic literature review identified 86 published patients in 52 reports up to December
    2023. These are clinically defined cases; most were reported before the STAT4 association and were not
    genotyped.
  evidence:
  - reference: PMID:39520387
    reference_title: "Disabling pansclerotic morphoea: a century of discovery."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "We identified 52 reports comprising 86 patients published up to December 2023."
    explanation: >-
      Cumulative published case count from a systematic literature review; a case tally, not a population
      prevalence estimate.
- population: Not specified (pansclerotic morphea, all ages)
  measure_type: UNKNOWN
  prevalence_class: BELOW_1_IN_1000000
  rate_high: 0.01
  notes: >-
    The single-cell study of pansclerotic morphea states a prevalence of less than 1 per 10,000,000,
    citing earlier sources; the measure type and population are not given. The figure concerns
    pansclerotic morphea generally rather than the genetically defined childhood form, and is an upper
    bound (rate_high records the 0.01 ceiling).
  evidence:
  - reference: PMID:37471168
    reference_title: "Pansclerotic morphea is characterized by IFN-γ responses priming dendritic cell fibroblast crosstalk to promote fibrosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "an extremely rare, difficult-to-treat disease, with a prevalence of less than 1 per 10,000,000"
    explanation: >-
      Introduction sentence restating a prevalence ceiling from cited literature; the paper's own data are
      transcriptomic, not epidemiological.
inheritance:
- name: Autosomal dominant
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >-
    Monoallelic STAT4 gain-of-function variants were inherited in an autosomal dominant pattern or arose
    de novo; p.His623Tyr has recurred de novo in an unrelated Chinese child. Expressivity is variable: in two of three families a first-degree relative carried milder
    disease (oral ulceration, mild skin disease or early-onset progressive swan-neck deformities of the
    hands), which the authors suggest may reflect genetic modifiers.
  evidence:
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We evaluated four patients from three unrelated families with an autosomal dominant pattern of inheritance of DPM."
    explanation: Documents autosomal dominant transmission across the three families.
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our identification of novel, autosomal dominantly inherited or de novo variants in STAT4 appears to be the first description of a gain-of-function variant in this gene and the first genetic link for DPM."
    explanation: States that the variants were either dominantly inherited or de novo.
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "additional genetic modifiers of disease severity could exist, which may account for the presence of a parent with milder disease in two of the three families"
    explanation: Records variable expressivity, with mildly affected parents in two of the three families.
genetic:
- name: STAT4
  gene_term:
    preferred_term: STAT4
    term:
      id: hgnc:11365
      label: STAT4
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >-
    Three heterozygous missense variants (p.His623Tyr, p.Ala635Val, p.Ala650Asp) were found in three
    unrelated kindreds, all in the region encoding the SH2 domain. They were absent from population
    databases and, in luciferase, phosphorylation and nuclear-localization assays, behaved as
    gain-of-function alleles. H623Y and A635V are predicted to stabilize the activated dimer, whereas A650D
    is predicted to act through a different intramonomer interaction. Clinically diagnosed DPM reported
    before 2023 was not genotyped, so the fraction of DPM explained by STAT4 is not known. No ClinGen
    gene-disease validity classification is cited here.
  evidence:
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genome sequencing revealed three novel heterozygous missense gain-of-function variants in STAT4."
    explanation: Identifies heterozygous STAT4 missense variants in all three affected kindreds.
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Each occurs in the region of STAT4 that encodes the SH2 domain"
    explanation: Locates all three variants in the SH2-domain-encoding region.
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Gain-of-function variants in STAT4 caused DPM in the families that we studied."
    explanation: The authors' causal conclusion for the gene-disease relationship.
  - reference: PMID:40518164
    reference_title: "[A case of autoinflammatory disease with STAT4 variant and localized scleroderma]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "基因检测结果显示患儿携带STAT4（NM_003151.4）c.1867C>T（p.His623Tyr）新发杂合变异"
    explanation: >-
      Chinese-language abstract: genetic testing showed that a 6-year-old girl carried a de novo
      heterozygous STAT4 c.1867C>T (p.His623Tyr) variant, the same allele as in one of the original
      families. She presented with erythema nodosum, ankle arthritis and fever before localized skin
      depression; the report frames her disease as autoinflammatory disease with localized scleroderma
      rather than full pansclerotic morphea.
pathophysiology:
- name: STAT4 SH2-Domain Gain-of-Function Signaling
  conforms_to: "jak_stat_pathway_activation#Constitutive STAT Activation and Nuclear Translocation"
  description: >-
    Heterozygous SH2-domain missense variants make STAT4 constitutively active. Variant STAT4 drives an
    IL6 promoter reporter in the absence of stimulation, shows raised phosphorylated STAT4 at baseline, and
    after interferon-alpha stimulation keeps phosphorylated STAT4 elevated for longer than wild type. Variant
    protein accumulates in the nucleus, and patient dermal fibroblasts show phosphorylated STAT4 at baseline.
    Persistent phosphorylation in the absence of new phosphorylation suggests that mutant dimers are more
    stable than wild-type dimers.
  biological_scale: MOLECULAR
  mechanism_confidence: ESTABLISHED
  genetic_context:
    variant_origin: GERMLINE
    functional_impact_category: GAIN_OF_FUNCTION
    zygosity: HETEROZYGOUS
    gene:
      preferred_term: STAT4
      term:
        id: hgnc:11365
        label: STAT4
    description: >-
      Monoallelic SH2-domain missense variants (H623Y, A635V, A650D), inherited dominantly or arising de novo.
  genes:
  - preferred_term: STAT4
    term:
      id: hgnc:11365
      label: STAT4
  molecular_functions:
  - preferred_term: STAT4 transcription activator activity
    term:
      id: GO:0001228
      label: DNA-binding transcription activator activity, RNA polymerase II-specific
    modifier: GAIN_OF_FUNCTION
  biological_processes:
  - preferred_term: STAT4 signaling
    modifier: INCREASED
    term:
      id: GO:0007259
      label: cell surface receptor signaling pathway via JAK-STAT
  evidence:
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "In unstimulated cells with variant STAT4, pSTAT4 levels were higher than those in cells transfected with control STAT4"
    explanation: Baseline hyperphosphorylation of variant STAT4 in a STAT1/STAT4-deficient cell line.
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "the increased levels of pSTAT4 were comparatively durable in cells containing variant STAT4"
    explanation: Prolonged phosphorylation after interferon-alpha stimulation, consistent with resistance to signal termination.
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "pSTAT4 was evident at baseline in primary skin fibroblasts from patients but not in fibroblasts from healthy donors despite these cells having similar levels of STAT4 expression"
    explanation: Shows constitutive STAT4 activation in patient-derived primary dermal fibroblasts.
  downstream:
  - target: Fibroblast Interleukin-6 Autoinflammatory Loop
    causal_link_type: DIRECT
    description: >-
      Variant STAT4 increases transcription from the IL6 promoter, a STAT4 target, and patient fibroblasts
      secrete excess interleukin-6.
    evidence:
    - reference: PMID:37256972
      reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Together, these data suggest that the gain-of-function STAT4 A635V variant causes an autoinflammatory loop, largely mediated by interleukin-6, which drives the fibroblast phenotype."
      explanation: Links the STAT4 variant directly to an interleukin-6 autoinflammatory loop in fibroblasts.
  - target: Lymphocyte Inflammatory Transcriptional Program
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      STAT4 is highly expressed in NK and T cells, and in these cells ruxolitinib reduced the inferred
      activity of IFNG, IFNA, TNF, IL6 and STAT1. The specific STAT4-dependent steps in lymphocytes are not
      resolved; interleukin-12-induced STAT4 phosphorylation in patient T cells was not increased.
    evidence:
    - reference: PMID:37256972
      reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Single-cell RNA sequencing revealed expression patterns consistent with an immunodysregulatory phenotype that were appropriately modified through JAK inhibition."
      explanation: Patient blood single-cell transcriptomes show an immunodysregulatory program that is reversed by JAK inhibition.
  - target: Neutropenia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Neutropenia resolved on JAK inhibition, which ties it to JAK-STAT signalling; which cell population
      carries the effect is not established.
    evidence:
    - reference: PMID:37256972
      reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: "His neutropenia resolved, inflammatory markers normalized, anemia decreased, and thrombocytopenia stabilized"
      explanation: Treatment response to JAK inhibition, so the link to STAT4 signalling is inferred.
  - target: Anemia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Anemia decreased on JAK inhibition; the mechanism is not established.
    evidence:
    - reference: PMID:37256972
      reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: "His neutropenia resolved, inflammatory markers normalized, anemia decreased, and thrombocytopenia stabilized"
      explanation: Treatment response to JAK inhibition, so the link to STAT4 signalling is inferred.
  - target: Thrombocytopenia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Thrombocytopenia stabilized on JAK inhibition; the mechanism is not established.
    evidence:
    - reference: PMID:37256972
      reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: "His neutropenia resolved, inflammatory markers normalized, anemia decreased, and thrombocytopenia stabilized"
      explanation: Treatment response to JAK inhibition, so the link to STAT4 signalling is inferred.
  - target: Pulmonary arterial hypertension
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Pulmonary hypertension improved in one patient after ruxolitinib was started; the vascular
      mechanism is not characterized.
    evidence:
    - reference: PMID:37256972
      reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: "Patient 2 has since begun therapy with ruxolitinib, with improvement in his pulmonary hypertension."
      explanation: Single-patient treatment response, so the link to STAT4 signalling is inferred.
- name: Fibroblast Interleukin-6 Autoinflammatory Loop
  description: >-
    Unstimulated dermal fibroblasts from patients secrete about 12 times as much interleukin-6 as fibroblasts
    from healthy donors. Variant-transfected cells also express more interleukin-6 and SOCS genes.
    Interleukin-6 itself reproduces the patient fibroblast defects in healthy-donor fibroblasts, which
    supports a self-sustaining autoinflammatory loop in the stroma. Anti-interleukin-6 treatment produced
    only a modest improvement in vitro, whereas upstream JAK inhibition with ruxolitinib reduced
    interleukin-6 secretion.
  biological_scale: CELLULAR
  mechanism_confidence: ESTABLISHED
  cell_types:
  - preferred_term: dermal fibroblast
    term:
      id: CL:0002551
      label: fibroblast of dermis
  biological_processes:
  - preferred_term: interleukin-6 production
    modifier: INCREASED
    term:
      id: GO:0032635
      label: interleukin-6 production
  - preferred_term: interleukin-6-mediated signaling
    modifier: INCREASED
    term:
      id: GO:0070102
      label: interleukin-6-mediated signaling pathway
  evidence:
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "unstimulated skin fibroblasts from patients secreted 12 times as much interleukin-6 as those from healthy donors"
    explanation: Quantifies interleukin-6 hypersecretion by patient dermal fibroblasts.
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "In vitro treatment with anti-interleukin-6 led to a modest improvement in fibroblast function but suggested that upstream targeting of this molecular pathway may be required to inhibit autoinflammation"
    explanation: Interleukin-6 blockade alone only partly reverses the fibroblast phenotype.
  downstream:
  - target: Impaired Fibroblast Wound Repair
    causal_link_type: DIRECT
    description: >-
      Pulsing healthy-donor fibroblasts with recombinant interleukin-6 reproduced the patient phenotype:
      reduced migration, failed scratch closure, reduced contraction and enlarged cells.
    evidence:
    - reference: PMID:37256972
      reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "interleukin-6 reduced the migration of fibroblasts derived from healthy donors, prevented scratch closure"
      explanation: Interleukin-6 is sufficient to impair fibroblast wound-closure functions.
- name: Impaired Fibroblast Wound Repair
  description: >-
    Patient dermal fibroblasts migrate slowly and fail to close a scratch wound, contract a collagen matrix
    poorly after TGF-beta stimulation, show disorganized F-actin with enlarged cell size, and secrete less
    procollagen alpha-1 while fibronectin secretion is unchanged. Ruxolitinib restored the rate of scratch
    closure in patient fibroblasts. This cellular defect is the proposed basis of the poor wound healing and
    chronic ulceration of DPM.
  biological_scale: CELLULAR
  mechanism_confidence: ESTABLISHED
  cell_types:
  - preferred_term: dermal fibroblast
    term:
      id: CL:0002551
      label: fibroblast of dermis
  biological_processes:
  - preferred_term: fibroblast migration
    modifier: DECREASED
    term:
      id: GO:0010761
      label: fibroblast migration
  - preferred_term: wound healing
    modifier: DECREASED
    term:
      id: GO:0042060
      label: wound healing
  evidence:
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Skin fibroblasts from a patient with STAT4 A635V did not migrate as rapidly as fibroblasts from healthy donors and ultimately did not close the induced gap"
    explanation: Patient fibroblasts fail a scratch wound-closure assay.
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Patient-derived fibroblasts had less contractility than fibroblasts from healthy donors"
    explanation: Defective collagen-matrix contraction, another component of wound repair.
  downstream:
  - target: Poor wound healing
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      The authors relate the fibroblast defects to the clinical failure of wound healing; the in vitro to
      in vivo step is inferential.
    evidence:
    - reference: PMID:37256972
      reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "In vitro, primary skin fibroblasts showed enhanced interleukin-6 secretion, with impaired wound healing, contraction of the collagen matrix, and matrix secretion."
      explanation: Summarizes the fibroblast wound-healing defect used to explain the clinical phenotype.
  - target: Skin ulcer
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Defective fibroblast repair is proposed to underlie the chronic, nonhealing skin ulcers.
  - target: Oral ulcer
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Mucosal ulceration is an early and consistent sign and resolved on ruxolitinib; the link to the
      fibroblast repair defect is inferred.
- name: Lymphocyte Inflammatory Transcriptional Program
  description: >-
    Single-cell RNA sequencing of patient peripheral-blood cells showed an immunodysregulatory profile in
    NK cells and T cells, which express STAT4 highly. Ruxolitinib reduced the inferred activity of
    inflammatory regulators including IFNG, IFNA, TNF, IL6 and STAT1. Th1 skewing was not observed, but
    T-cell subsets showed evidence of exhaustion. Skin biopsies show a subepidermal inflammatory infiltrate
    composed mostly of CD3-positive T cells. How STAT4 gain of function produces the systemic cytopenias
    and hypogammaglobulinemia is not established.
  biological_scale: CELLULAR
  mechanism_confidence: PROVISIONAL
  cell_types:
  - preferred_term: natural killer cell
    term:
      id: CL:0000623
      label: natural killer cell
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  biological_processes:
  - preferred_term: inflammatory response
    modifier: INCREASED
    term:
      id: GO:0006954
      label: inflammatory response
  evidence:
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ruxolitinib treatment decreased the activity of genes such as IFNG, IFNA, TNF, IL6 and STAT1, which control multiple inflammatory pathways"
    explanation: JAK inhibition reverses an inflammatory transcriptional program in patient NK and T cells.
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "whereas interleukin-12-induced phosphorylation of STAT4 in patient peripheral-blood T cells, typical of type 1 helper T (Th1) cell skewing, was not affected, although T-cell subsets had evidence for exhaustion"
    explanation: >-
      Interleukin-12-induced STAT4 phosphorylation in patient T cells was normal, while T-cell subsets
      showed exhaustion, so the lymphocyte defect is not simple Th1 hyperactivation.
  downstream:
  - target: Acute phase response
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Inflammatory markers normalized when the inflammatory program was suppressed by ruxolitinib.
    evidence:
    - reference: PMID:37256972
      reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "His neutropenia resolved, inflammatory markers normalized, anemia decreased, and thrombocytopenia stabilized"
      explanation: Reversal of inflammatory markers with JAK inhibition ties them to the JAK-STAT-driven program.
  - target: Progressive Deep Tissue Sclerosis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Lesional skin combines a T-cell-rich inflammatory infiltrate with alpha smooth-muscle actin staining
      indicative of fibrosis. How the STAT4-driven inflammation produces deep sclerosis is not resolved:
      patient fibroblasts in vitro secreted less, not more, procollagen.
    evidence:
    - reference: PMID:37256972
      reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "showed extensive staining for alpha smooth-muscle actin, a finding consistent with fibrosis, and CD3-positive staining in most of the subepidermal lymphocytes, which confirmed an inflammatory infiltrate composed of mostly T cells"
      explanation: Co-localizes T-cell inflammation with fibrosis in STAT4-variant patient skin; this is co-occurrence, not a demonstrated causal step.
- name: Type II Interferon-Driven Fibroblast-Dendritic Cell Crosstalk
  description: >-
    Single-cell and spatial transcriptomics of lesional skin from one patient with pansclerotic morphea
    showed a dominant type II interferon response, with T cells as the main IFN-gamma source.
    IFN-gamma-responsive CXCL9+ fibroblasts lay near the T cells and were related to profibrotic, TGF-beta-responsive
    COL8A1+ myofibroblasts, with cDC2B dendritic cells as a predicted communication hub. TGF-beta and
    IFN-gamma synergistically induced CXCL9 and CXCL10 in fibroblasts, and serum CXCL9 tracked disease
    activity in a separate pansclerotic morphea cohort. The patient's STAT4 genotype was not reported, so this
    node is a tissue-level model of pansclerotic morphea that has not been tied to the STAT4 lesion.
  biological_scale: TISSUE
  mechanism_confidence: PROVISIONAL
  cell_types:
  - preferred_term: dermal fibroblast
    term:
      id: CL:0002551
      label: fibroblast of dermis
  - preferred_term: myofibroblast
    term:
      id: CL:0000186
      label: myofibroblast cell
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  - preferred_term: cDC2B conventional dendritic cell
    term:
      id: CL:0000990
      label: conventional dendritic cell
  biological_processes:
  - preferred_term: response to IFN-gamma
    modifier: INCREASED
    term:
      id: GO:0034341
      label: response to type II interferon
  - preferred_term: myofibroblast differentiation
    modifier: INCREASED
    term:
      id: GO:0036446
      label: myofibroblast differentiation
  locations:
  - preferred_term: dermis
    term:
      id: UBERON:0002067
      label: dermis
  evidence:
  - reference: PMID:37471168
    reference_title: "Pansclerotic morphea is characterized by IFN-γ responses priming dendritic cell fibroblast crosstalk to promote fibrosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Fibrotic skin was characterized by prominent type II IFN response, accompanied by infiltrating myeloid cells, B cells, and T cells, which were the main IFN-γ source."
    explanation: Patient skin transcriptomics establish a type II interferon-dominated lesional milieu.
  - reference: PMID:37471168
    reference_title: "Pansclerotic morphea is characterized by IFN-γ responses priming dendritic cell fibroblast crosstalk to promote fibrosis."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "In vitro, TGF-β and IFN-γ synergistically increased CXCL9 and CXCL10 expression, contributing to the perpetuation of IFN-γ responses."
    explanation: Cultured dermal fibroblast experiment showing a feed-forward chemokine loop.
  - reference: PMID:37471168
    reference_title: "Pansclerotic morphea is characterized by IFN-γ responses priming dendritic cell fibroblast crosstalk to promote fibrosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We found that serum levels of CXCL9 were positively associated with higher LoSAI scores"
    explanation: An IFN-gamma-inducible chemokine tracks clinical disease activity in a nine-patient cohort.
  downstream:
  - target: Progressive Deep Tissue Sclerosis
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      CXCL9+ inflammatory fibroblasts are related to COL8A1+ myofibroblasts with a TGF-beta response and high
      extracellular-matrix gene expression.
    evidence:
    - reference: PMID:37471168
      reference_title: "Pansclerotic morphea is characterized by IFN-γ responses priming dendritic cell fibroblast crosstalk to promote fibrosis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "CXCL9+ fibroblasts were related to profibrotic COL8A1+ myofibroblasts, which had enriched TGF-β response."
      explanation: Places the interferon-responsive fibroblast state upstream of profibrotic myofibroblasts in lesional skin.
- name: Progressive Deep Tissue Sclerosis
  description: >-
    Rapidly progressive sclerosis involves all layers of the skin and extends circumferentially into
    subcutaneous fat, fascia, muscle and bone, and can involve mucous membranes. Imaging shows deep-tissue
    inflammation and sclerosis from subcutis to muscle. Fibrosis of internal organs is typically absent,
    distinguishing DPM from systemic sclerosis. Deep sclerosis causes contractures, musculoskeletal atrophy
    and articular ankylosis.
  biological_scale: TISSUE
  mechanism_confidence: ESTABLISHED
  biological_processes:
  - preferred_term: extracellular matrix organization
    modifier: INCREASED
    term:
      id: GO:0030198
      label: extracellular matrix organization
  locations:
  - preferred_term: dermis
    term:
      id: UBERON:0002067
      label: dermis
  - preferred_term: subcutaneous fat
    term:
      id: UBERON:0002190
      label: subcutaneous adipose tissue
  - preferred_term: fascia
    term:
      id: UBERON:0008982
      label: fascia
  - preferred_term: skeletal muscle
    term:
      id: UBERON:0001134
      label: skeletal muscle tissue
  evidence:
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Musculoskeletal imaging showed deep-tissue inflammation and sclerosis of several levels from subcutis to muscle, findings consistent with DPM."
    explanation: Imaging of the STAT4-variant patients documents sclerosis from subcutis to muscle.
  - reference: PMID:39520387
    reference_title: "Disabling pansclerotic morphoea: a century of discovery."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "DPM is characterized by rapid sclerosis with circumferential involvement that frequently extends to the fascia, muscle and bone."
    explanation: Literature-wide synthesis of the depth and pattern of sclerosis.
  - reference: PMID:39520387
    reference_title: "Disabling pansclerotic morphoea: a century of discovery."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Internal organ fibrosis is typically absent."
    explanation: Records the absence of visceral fibrosis that separates DPM from systemic sclerosis.
  downstream:
  - target: Morphea
    causal_link_type: DIRECT
  - target: Joint contracture
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:37256972
      reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: BACKGROUND
      snippet: "rapidly progressive deep fibrosis involving the mucous membranes, dermis, subcutaneous fat, fascia, muscles, and bone, leading to contractures, musculoskeletal atrophy, and articular ankylosis"
      explanation: Introduction sentence stating that deep fibrosis leads to contractures, atrophy and ankylosis.
  - target: Skeletal muscle atrophy
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:37256972
      reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: BACKGROUND
      snippet: "rapidly progressive deep fibrosis involving the mucous membranes, dermis, subcutaneous fat, fascia, muscles, and bone, leading to contractures, musculoskeletal atrophy, and articular ankylosis"
      explanation: Introduction sentence stating that deep fibrosis leads to musculoskeletal atrophy.
  - target: Ankylosis
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:37256972
      reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: BACKGROUND
      snippet: "rapidly progressive deep fibrosis involving the mucous membranes, dermis, subcutaneous fat, fascia, muscles, and bone, leading to contractures, musculoskeletal atrophy, and articular ankylosis"
      explanation: Introduction sentence stating that deep fibrosis leads to articular ankylosis.
  - target: Skin ulcer
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Deep sclerosis with musculoskeletal atrophy is described as resulting in cutaneous ulceration; the
      intermediate steps are not specified.
    evidence:
    - reference: PMID:30838436
      reference_title: "Challenges in the diagnosis and treatment of disabling pansclerotic morphea of childhood: case-based review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: "the rapid progression of deep musculoskeletal atrophy resulting in cutaneous ulceration and severe joint contractures"
      explanation: Case-based review linking deep atrophic sclerosis to ulceration and contractures.
phenotypes:
- category: Dermatological
  name: Morphea
  frequency: OBLIGATE
  phenotype_term:
    preferred_term: Pansclerotic morphea
    term:
      id: HP:0012344
      label: Morphea
  description: >-
    Sclerotic skin lesions that spread rapidly and become generalized and full-thickness, often with
    circumferential limb involvement. Biopsies are consistent with morphea, with thickened, hyalinized
    collagen bundles in the reticular dermis. The HPO term is defined as isolated patches of hardened skin,
    which understates the pansclerotic extent; it is used as the closest available morphea term.
  evidence:
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All four patients had had disease onset before 5 years of age, with signs of mucosal ulcerations and skin sclerosis"
    explanation: Skin sclerosis was present in all four STAT4-variant patients.
  - reference: PMID:29455178
    reference_title: "Disabling pansclerotic morphoea of childhood."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There was marked thickening of collagen bundles in the lower reticular dermis."
    explanation: Histology of a DPM skin lesion.
- category: Dermatological
  name: Poor wound healing
  phenotype_term:
    preferred_term: Poor wound healing
    term:
      id: HP:0001058
      label: Poor wound healing
  evidence:
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    quote_role: BACKGROUND
    evidence_source: HUMAN_CLINICAL
    snippet: "Disabling pansclerotic morphea (DPM) is a rare systemic inflammatory disorder, characterized by poor wound healing, fibrosis, cytopenias, hypogammaglobulinemia, and squamous-cell carcinoma."
    explanation: Poor wound healing is a defining feature in the description of the disease.
- category: Dermatological
  name: Skin ulcer
  phenotype_term:
    preferred_term: Chronic nonhealing skin ulcer
    term:
      id: HP:0200042
      label: Skin ulcer
  description: >-
    Chronic, nonhealing ulcers occur on the legs and on the upper limbs, trunk and head. They are refractory
    to treatment and are the setting in which cutaneous squamous cell carcinoma develops.
  evidence:
  - reference: PMID:18048875
    reference_title: "Disabling pansclerotic morphea of childhood poses a high risk of chronic ulceration of the skin and squamous cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Five patients suffered from chronic nonhealing leg ulcers (17%), but ulcers were present on other parts of the body (upper limbs, trunk, head) as well (n = 6)."
    explanation: Frequency and distribution of chronic ulcers across 30 published and new DPMC patients.
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "three of the patients had spreading of their rash and worsening ulcerations, with rapid development of contractures, muscular atrophy, and impairments in mobility"
    explanation: Progressive ulceration in STAT4-variant patients despite immunosuppression.
  sequelae:
  - target: Squamous cell carcinoma of the skin
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Squamous cell carcinoma arises within areas of long-standing chronic ulceration.
    evidence:
    - reference: PMID:19250408
      reference_title: "Lower lip squamous cell carcinoma in disabling pansclerotic morphea of childhood."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "To our knowledge there are only two cases of SCC in patients with DPMC that developed within areas of chronic skin ulceration."
      explanation: Previously reported DPMC-associated SCCs arose within chronic ulcers.
    - reference: PMID:28543434
      reference_title: "Metastatic Squamous Cell Carcinoma in a Patient with Disabling Pansclerotic Morphea of Childhood."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Disabling pansclerotic morphea of childhood (DPMC) is a rare disorder that confers a risk of developing ulcer-related squamous cell carcinoma (SCC)."
      explanation: States the ulcer-related SCC risk in DPMC.
- category: Oral
  name: Oral ulcer
  phenotype_term:
    preferred_term: Oral mucosal ulceration
    term:
      id: HP:0000155
      label: Oral ulcer
  description: >-
    Mucosal ulceration was an early sign in all four STAT4-variant patients (beginning at 3 years of age in
    one) and was also seen in mildly affected relatives. Oral ulcers largely resolved on ruxolitinib.
  evidence:
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Two of the families had first-degree relatives with oral ulcerations, mild skin disease, or early-onset progressive hand swan-neck deformities"
    explanation: Oral ulceration occurs in affected families, including mildly affected relatives.
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "After 11 months of therapy, the rash and oral ulcers had largely resolved."
    explanation: Documents oral ulcers in a treated patient and their response to ruxolitinib.
- category: Dermatological
  name: Panniculitis
  phenotype_term:
    preferred_term: Hyaline panniculitis
    term:
      id: HP:0012490
      label: Panniculitis
  evidence:
  - reference: PMID:7356347
    reference_title: "Disabling pansclerotic morphea of children."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lymphocytic inflammation and hyaline pannicultitis were observed on biopsy specimens in some cases."
    explanation: Biopsy finding in the original 14-child series (the source spells it "pannicultitis").
- category: Musculoskeletal
  name: Joint contracture
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Joint contracture
    term:
      id: HP:0034392
      label: Joint contracture
  description: >-
    Painful, disabling contractures of the hands, hips, knees and ankles develop as sclerosis reaches the
    deep tissues and lead to immobility.
  evidence:
  - reference: PMID:18048875
    reference_title: "Disabling pansclerotic morphea of childhood poses a high risk of chronic ulceration of the skin and squamous cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The majority of patients had an aggressive course with deep sclerotic lesions leading to joint contractures and immobility."
    explanation: Contractures in most of 30 DPMC patients.
  - reference: PMID:17143989
    reference_title: "Efficacy of bosentan in treatment of unresponsive cutaneous ulceration in disabling pansclerotic morphea in children."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "rapid progression of deep cutaneous fibrosis extending into the muscle fascia with disabling joint contractures of the hips, knees, ankles, and fingers"
    explanation: Distribution of contractures in a single case.
- category: Musculoskeletal
  name: Skeletal muscle atrophy
  phenotype_term:
    preferred_term: Musculoskeletal atrophy
    term:
      id: HP:0003202
      label: Skeletal muscle atrophy
  evidence:
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "three of the patients had spreading of their rash and worsening ulcerations, with rapid development of contractures, muscular atrophy, and impairments in mobility"
    explanation: Muscular atrophy developed in three of four STAT4-variant patients.
- category: Musculoskeletal
  name: Ankylosis
  phenotype_term:
    preferred_term: Articular ankylosis
    term:
      id: HP:0031013
      label: Ankylosis
  evidence:
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "rapidly progressive deep fibrosis involving the mucous membranes, dermis, subcutaneous fat, fascia, muscles, and bone, leading to contractures, musculoskeletal atrophy, and articular ankylosis"
    explanation: Articular ankylosis as an end-stage consequence of deep fibrosis.
- category: Musculoskeletal
  name: Arthritis
  phenotype_term:
    preferred_term: Polyarthritis with joint swelling
    term:
      id: HP:0001369
      label: Arthritis
  description: >-
    Joint swelling or polyarthritis was the first manifestation in two STAT4-variant patients, at 3 years of
    age in one.
  evidence:
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the first symptom that developed in Patient 2 was polyarthritis"
    explanation: Polyarthritis as a presenting feature.
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "an autoinflammatory disease with joint swelling at 3 years of age, hand contractures at 7 years of age, and progressive skin ulcerations beginning at 8 years of age"
    explanation: Joint swelling preceded contractures and ulceration in another patient.
- category: Hematological
  name: Neutropenia
  phenotype_term:
    preferred_term: Mild neutropenia
    term:
      id: HP:0001875
      label: Decreased total neutrophil count
  evidence:
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Laboratory evaluations showed mild neutropenia and lymphopenia, especially with respect to CD4+ T cells, and elevated serum inflammatory markers in three of the four patients."
    explanation: Neutropenia in three of four STAT4-variant patients.
- category: Immunological
  name: Lymphopenia
  phenotype_term:
    preferred_term: Lymphopenia, predominantly CD4+ T cells
    term:
      id: HP:0001888
      label: Decreased total lymphocyte count
  evidence:
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Laboratory evaluations showed mild neutropenia and lymphopenia, especially with respect to CD4+ T cells, and elevated serum inflammatory markers in three of the four patients."
    explanation: Lymphopenia, especially of CD4+ T cells, in three of four patients.
- category: Hematological
  name: Anemia
  phenotype_term:
    preferred_term: Anemia
    term:
      id: HP:0001903
      label: Anemia
  evidence:
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "His neutropenia resolved, inflammatory markers normalized, anemia decreased, and thrombocytopenia stabilized"
    explanation: Anemia, with thrombocytopenia and neutropenia, in a STAT4-variant patient, improving on ruxolitinib.
- category: Hematological
  name: Thrombocytopenia
  phenotype_term:
    preferred_term: Thrombocytopenia
    term:
      id: HP:0001873
      label: Thrombocytopenia
  evidence:
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "His neutropenia resolved, inflammatory markers normalized, anemia decreased, and thrombocytopenia stabilized"
    explanation: Thrombocytopenia in a STAT4-variant patient, stabilized on ruxolitinib.
- category: Immunological
  name: Decreased circulating IgG concentration
  phenotype_term:
    preferred_term: Hypogammaglobulinemia (low IgG)
    term:
      id: HP:0004315
      label: Decreased circulating IgG concentration
  description: >-
    Low IgG and IgA in three of four STAT4-variant patients, with no detectable autoantibodies. One patient
    required intravenous immunoglobulin replacement. This contrasts with the polyclonal
    hypergammaglobulinemia reported in the original 1980 clinical series of genetically undefined
    patients.
  evidence:
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "serum levels of immunoglobulin classes IgG and IgA were reduced in three of the four patients"
    explanation: Reduced IgG in three of four patients.
  - reference: PMID:7356347
    reference_title: "Disabling pansclerotic morphea of children."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "Laboratory data were characterized by a polyclonal elevation of gamma-globulin level and by peripheral eosinophilia."
    explanation: >-
      The original clinical series reported raised rather than reduced gamma-globulin, so
      hypogammaglobulinemia may be specific to the STAT4-defined cases rather than to all clinically
      defined DPM.
  sequelae:
  - target: Recurrent infections
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Hypogammaglobulinemia severe enough to need immunoglobulin replacement is a plausible contributor to
      the recurrent infections; the source does not analyse the link, and lymphopenia, neutropenia and
      open ulcers may contribute.
- category: Immunological
  name: Decreased circulating IgA concentration
  phenotype_term:
    preferred_term: IgA deficiency
    term:
      id: HP:0002720
      label: Decreased circulating IgA concentration
  evidence:
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "serum levels of immunoglobulin classes IgG and IgA were reduced in three of the four patients"
    explanation: Reduced IgA in three of four patients; IgA deficiency persisted on ruxolitinib in one.
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "normal IgG and IgM levels, with persistent IgA deficiency"
    explanation: IgA deficiency persisted after IgG normalized on treatment.
- category: Immunological
  name: Acute phase response
  phenotype_term:
    preferred_term: Elevated serum inflammatory markers
    term:
      id: HP:0033331
      label: Acute phase response
  evidence:
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Laboratory evaluations showed mild neutropenia and lymphopenia, especially with respect to CD4+ T cells, and elevated serum inflammatory markers in three of the four patients."
    explanation: Raised inflammatory markers in three of four patients.
- category: Hematological
  name: Eosinophilia
  phenotype_term:
    preferred_term: Peripheral eosinophilia
    term:
      id: HP:0001880
      label: Increased total eosinophil count
  description: Reported in the original clinical series; not reported in the STAT4-variant patients.
  evidence:
  - reference: PMID:7356347
    reference_title: "Disabling pansclerotic morphea of children."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Laboratory data were characterized by a polyclonal elevation of gamma-globulin level and by peripheral eosinophilia."
    explanation: Peripheral eosinophilia in the 14-child series.
- category: Immunological
  name: Recurrent infections
  phenotype_term:
    preferred_term: Recurrent infections
    term:
      id: HP:0002719
      label: Recurrent infections
  evidence:
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Two patients also had recurrent infections, and squamous-cell carcinoma had developed in one patient."
    explanation: Recurrent infections in two of four STAT4-variant patients.
- category: Neoplasm
  name: Squamous cell carcinoma of the skin
  phenotype_term:
    preferred_term: Ulcer-associated cutaneous squamous cell carcinoma
    term:
      id: HP:0006739
      label: Squamous cell carcinoma of the skin
  description: >-
    Squamous cell carcinoma develops in adolescence or early adulthood, usually within chronic ulcers, and
    can metastasize. It occurred in 2 of 30 patients (6.7%) in one literature series and in one of four
    STAT4-variant patients.
  evidence:
  - reference: PMID:18048875
    reference_title: "Disabling pansclerotic morphea of childhood poses a high risk of chronic ulceration of the skin and squamous cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Two patients developed a squamous cell carcinoma at the age of 16 years and 19 years, respectively (6.7%)."
    explanation: SCC frequency and age at onset in a combined case series.
  - reference: PMID:28543434
    reference_title: "Metastatic Squamous Cell Carcinoma in a Patient with Disabling Pansclerotic Morphea of Childhood."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We describe a young man with long-standing DPMC and SCC with lung metastasis."
    explanation: SCC in DPMC can metastasize.
- category: Cardiovascular
  name: Pulmonary arterial hypertension
  phenotype_term:
    preferred_term: Pulmonary hypertension
    term:
      id: HP:0002092
      label: Pulmonary arterial hypertension
  description: >-
    A less frequent finding in STAT4-variant patients; it improved in one patient on ruxolitinib. The source
    does not specify the haemodynamic category, so the arterial term is a closest fit.
  evidence:
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pulmonary nodules and infiltrates, pulmonary and portal hypertension, rapid-onset blindness (glaucoma and cataracts resulting in surgery), and sensorineural hearing loss were less frequent findings."
    explanation: Pulmonary hypertension among the less frequent findings.
- category: Respiratory
  name: Restrictive ventilatory defect
  phenotype_term:
    preferred_term: Restrictive pulmonary disease
    term:
      id: HP:0002091
      label: Restrictive ventilatory defect
  description: >-
    Restrictive pulmonary disease is named among the causes of morbidity and mortality in DPM. The cited
    sentence is the NEJM report's background framing of clinically defined DPM, not a measured frequency in
    the STAT4 cohort.
  evidence:
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    quote_role: BACKGROUND
    evidence_source: HUMAN_CLINICAL
    snippet: "DPM is associated with high morbidity and mortality due to squamous-cell carcinoma, restrictive pulmonary disease, sepsis, and gangrene"
    explanation: Names restrictive pulmonary disease as a cause of morbidity and mortality in DPM.
- category: Respiratory
  name: Pulmonary nodule
  phenotype_term:
    preferred_term: Pulmonary nodule
    term:
      id: HP:0033608
      label: Pulmonary nodule
  evidence:
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pulmonary nodules and infiltrates, pulmonary and portal hypertension, rapid-onset blindness (glaucoma and cataracts resulting in surgery), and sensorineural hearing loss were less frequent findings."
    explanation: Pulmonary nodules among the less frequent findings.
- category: Respiratory
  name: Pulmonary infiltrates
  phenotype_term:
    preferred_term: Pulmonary infiltrates
    term:
      id: HP:0002113
      label: Pulmonary infiltrates
  evidence:
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pulmonary nodules and infiltrates, pulmonary and portal hypertension, rapid-onset blindness (glaucoma and cataracts resulting in surgery), and sensorineural hearing loss were less frequent findings."
    explanation: Pulmonary infiltrates among the less frequent findings.
- category: Gastrointestinal
  name: Portal hypertension
  phenotype_term:
    preferred_term: Portal hypertension
    term:
      id: HP:0001409
      label: Portal hypertension
  evidence:
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pulmonary nodules and infiltrates, pulmonary and portal hypertension, rapid-onset blindness (glaucoma and cataracts resulting in surgery), and sensorineural hearing loss were less frequent findings."
    explanation: Portal hypertension among the less frequent findings.
- category: Ophthalmological
  name: Glaucoma
  phenotype_term:
    preferred_term: Glaucoma
    term:
      id: HP:0000501
      label: Glaucoma
  evidence:
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pulmonary nodules and infiltrates, pulmonary and portal hypertension, rapid-onset blindness (glaucoma and cataracts resulting in surgery), and sensorineural hearing loss were less frequent findings."
    explanation: Glaucoma among the less frequent findings.
- category: Ophthalmological
  name: Cataract
  phenotype_term:
    preferred_term: Cataract
    term:
      id: HP:0000518
      label: Cataract
  evidence:
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pulmonary nodules and infiltrates, pulmonary and portal hypertension, rapid-onset blindness (glaucoma and cataracts resulting in surgery), and sensorineural hearing loss were less frequent findings."
    explanation: Cataract among the less frequent findings.
- category: Audiological
  name: Sensorineural hearing impairment
  phenotype_term:
    preferred_term: Sensorineural hearing loss
    term:
      id: HP:0000407
      label: Sensorineural hearing impairment
  evidence:
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pulmonary nodules and infiltrates, pulmonary and portal hypertension, rapid-onset blindness (glaucoma and cataracts resulting in surgery), and sensorineural hearing loss were less frequent findings."
    explanation: Sensorineural hearing loss among the less frequent findings.
- category: Infectious
  name: Sepsis
  phenotype_term:
    preferred_term: Sepsis
    term:
      id: HP:0100806
      label: Sepsis
  description: A leading cause of death in DPMC.
  evidence:
  - reference: PMID:18048875
    reference_title: "Disabling pansclerotic morphea of childhood poses a high risk of chronic ulceration of the skin and squamous cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Four patients died because of complications of the disease such as sepsis or gangrene."
    explanation: Sepsis as a fatal complication.
- category: Vascular
  name: Gangrene
  phenotype_term:
    preferred_term: Gangrene
    term:
      id: HP:0100758
      label: Gangrene
  evidence:
  - reference: PMID:18048875
    reference_title: "Disabling pansclerotic morphea of childhood poses a high risk of chronic ulceration of the skin and squamous cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Four patients died because of complications of the disease such as sepsis or gangrene."
    explanation: Gangrene as a fatal complication.
treatments:
- name: Ruxolitinib
  description: >-
    Oral JAK1/2 inhibitor. In patient fibroblasts it reduced interleukin-6 secretion, phosphorylated STAT4
    and its nuclear localization, and restored scratch-wound closure. In two treated STAT4-variant patients
    it cleared rash and oral ulcers, normalized inflammatory markers, resolved neutropenia and improved
    pulmonary hypertension without reported adverse events. JAK inhibitors are not approved for DPM; the
    authors propose this approach for refractory disease.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: ruxolitinib
      term:
        id: CHEBI:66919
        label: ruxolitinib
  evidence:
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Inhibition of Janus kinase (JAK)-STAT signaling with ruxolitinib led to improvement in the hyperinflammatory fibroblast phenotype in vitro and resolution of inflammatory markers and clinical symptoms in treated patients, without adverse effects."
    explanation: Clinical and in vitro response to ruxolitinib in STAT4-variant DPM.
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patient 2 has since begun therapy with ruxolitinib, with improvement in his pulmonary hypertension."
    explanation: Improvement in pulmonary hypertension on ruxolitinib.
  - reference: PMID:40518164
    reference_title: "[A case of autoinflammatory disease with STAT4 variant and localized scleroderma]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "经激素及芦可替尼（早5.0 mg+晚2.5 mg）治疗后明显缓解"
    explanation: >-
      Chinese-language abstract: after glucocorticoids and ruxolitinib (5.0 mg morning, 2.5 mg evening)
      the STAT4 p.His623Tyr patient improved markedly, an independent report of response to JAK
      inhibition.
  target_mechanisms:
  - target: STAT4 SH2-Domain Gain-of-Function Signaling
    description: Blocks the JAK kinases upstream of STAT4 phosphorylation.
    evidence:
    - reference: PMID:37256972
      reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Ruxolitinib treatment also reduced the total amount of pSTAT4 and its nuclear localization in unstimulated U3A cells and patient fibroblasts"
      explanation: Ruxolitinib lowers constitutive STAT4 activation.
  - target: Fibroblast Interleukin-6 Autoinflammatory Loop
    evidence:
    - reference: PMID:37256972
      reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Ruxolitinib significantly reduced interleukin-6 secretion at concentrations achievable in serum"
      explanation: Ruxolitinib suppresses fibroblast interleukin-6 hypersecretion.
  - target: Impaired Fibroblast Wound Repair
    evidence:
    - reference: PMID:37256972
      reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "ruxolitinib enhanced the rate of scratch closure of patient fibroblasts to one nearly identical to that of fibroblasts from healthy donors"
      explanation: Ruxolitinib restores fibroblast wound closure in vitro.
  - target: Lymphocyte Inflammatory Transcriptional Program
    evidence:
    - reference: PMID:37256972
      reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "ruxolitinib treatment decreased the activity of genes such as IFNG, IFNA, TNF, IL6 and STAT1, which control multiple inflammatory pathways"
      explanation: Ruxolitinib reverses the lymphocyte inflammatory program in a treated patient.
- name: Methotrexate and Systemic Corticosteroids
  description: >-
    The most commonly used regimen in reported cases, often combined with ultraviolet A phototherapy.
    Responses are limited; DPM is generally refractory to glucocorticoids and conventional immunosuppression.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: methotrexate
      term:
        id: CHEBI:44185
        label: methotrexate
    - preferred_term: corticosteroid
      term:
        id: CHEBI:50858
        label: corticosteroid
  evidence:
  - reference: PMID:30838436
    reference_title: "Challenges in the diagnosis and treatment of disabling pansclerotic morphea of childhood: case-based review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Methotrexate and corticosteroids have been the most commonly utilized."
    explanation: Methotrexate and corticosteroids are the most frequently used agents across 37 reported cases.
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "DPM is refractory to therapy, including systemic glucocorticoids, immunosuppression, and autologous stem-cell transplantation."
    explanation: Conventional immunosuppression generally fails to halt progression.
- name: Mycophenolate Mofetil
  description: Anecdotally effective; subjective improvement was reported with prednisolone and mycophenolate mofetil.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: mycophenolate mofetil
      term:
        id: CHEBI:8764
        label: mycophenolate mofetil
  evidence:
  - reference: PMID:30838436
    reference_title: "Challenges in the diagnosis and treatment of disabling pansclerotic morphea of childhood: case-based review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "MMF has been anecdotally effective."
    explanation: Anecdotal benefit across reported cases.
- name: Tocilizumab
  description: >-
    Anti-interleukin-6 receptor monoclonal antibody, used off label in refractory pansclerotic morphea. In
    two children it reduced disease activity and halted progression. Neither child was genotyped.
  therapeutic_modality: MONOCLONAL_ANTIBODY
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: tocilizumab
      term:
        id: NCIT:C84217
        label: Tocilizumab
  evidence:
  - reference: PMID:28980909
    reference_title: "Tocilizumab in two children with pansclerotic morphoea: a hopeful therapy for refractory cases?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We describe the first two cases of children with PM refractory to different immunosuppressive agents in which the use of TCZ reduced disease activity and stopped disease progression."
    explanation: Case-level response to interleukin-6 receptor blockade in refractory childhood pansclerotic morphea.
  target_mechanisms:
  - target: Fibroblast Interleukin-6 Autoinflammatory Loop
    description: Blocks the interleukin-6 receptor; in STAT4-variant fibroblasts, interleukin-6 blockade alone gave only modest in vitro improvement.
- name: Ultraviolet A Phototherapy
  description: Phototherapy, often with methotrexate and corticosteroids, has been reported to reduce skin thickness and plaque stiffness.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Phototherapy
    term:
      id: NCIT:C15301
      label: Phototherapy
  evidence:
  - reference: PMID:30838436
    reference_title: "Challenges in the diagnosis and treatment of disabling pansclerotic morphea of childhood: case-based review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Phototherapy has been documented to be reducing skin thickness and stiffness of plaques."
    explanation: Reported benefit of phototherapy on skin thickness.
- name: Bosentan
  description: >-
    Dual endothelin receptor antagonist used for refractory ischemic ulcers; improvement of ulcers, skin
    thickness and joint mobility was reported in a single child.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: bosentan
      term:
        id: CHEBI:51450
        label: bosentan
  evidence:
  - reference: PMID:17143989
    reference_title: "Efficacy of bosentan in treatment of unresponsive cutaneous ulceration in disabling pansclerotic morphea in children."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "limb ulcers improved, with resolution of the widespread sclerotic skin lesions"
    explanation: Single-case response of ulcers and sclerosis to bosentan.
- name: Sildenafil with Acellular Matrix Wound Dressing
  description: >-
    Sildenafil combined with repeated application of porcine small-intestinal submucosa acellular matrix
    markedly improved chronic leg ulcers in reported cases.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: sildenafil
      term:
        id: CHEBI:9139
        label: sildenafil
  evidence:
  - reference: PMID:18048875
    reference_title: "Disabling pansclerotic morphea of childhood poses a high risk of chronic ulceration of the skin and squamous cell carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report on marked improvement of chronic leg ulcers by a combination of sildenafil 3 x 20 mg/day and repeated application of a porcine small intestinal submucosal acellular matrix."
    explanation: Reported ulcer response to combined sildenafil and acellular matrix.
- name: Intravenous Immunoglobulin Replacement
  description: Used for hypogammaglobulinemia with low IgG in a STAT4-variant patient.
  therapeutic_modality: PROTEIN_REPLACEMENT
  treatment_term:
    preferred_term: Intravenous immunoglobulin therapy
    term:
      id: NCIT:C121331
      label: Intravenous Immunoglobulin Therapy
  evidence:
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He continues to receive intravenous immunoglobulin (2 g per kilogram of body weight) for IgG levels below 1000 mg per deciliter"
    explanation: Immunoglobulin replacement for low IgG.
- name: Physical Therapy
  description: >-
    The mainstay of non-pharmacological management, aimed at maintaining function and muscle strength and
    preventing flexion contractures.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Physical therapy
    term:
      id: NCIT:C15302
      label: Physical Therapy
  evidence:
  - reference: PMID:29455178
    reference_title: "Disabling pansclerotic morphoea of childhood."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "Physical therapy remains the mainstay of non-pharmacological management and may aid in maintaining functional ability, muscle strength and prevention of flexion contractures."
    explanation: Role of physical therapy in preserving function.
diagnosis:
- name: Skin biopsy
  description: >-
    The clinical diagnosis of DPM rests on skin histology showing deep sclerosis with an inflammatory
    infiltrate; in the STAT4 families the diagnosis had been made this way before genetic testing.
  presence: PRESENT
  evidence:
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "both had received diagnoses of DPM by means of skin biopsy"
    explanation: Skin biopsy established the clinical diagnosis in the index patients.
- name: Musculoskeletal imaging
  description: >-
    Imaging shows how deep the inflammation and sclerosis extend, from subcutis to muscle, which is what
    separates the pansclerotic form from superficial morphea.
  presence: PRESENT
  evidence:
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Musculoskeletal imaging showed deep-tissue inflammation and sclerosis of several levels from subcutis to muscle, findings consistent with DPM."
    explanation: Imaging documented the depth of tissue involvement characteristic of DPM.
- name: Genome sequencing for STAT4 variants
  description: >-
    Sequencing identifies the heterozygous STAT4 gain-of-function variant that defines the genetic form
    and points to JAK inhibition as a treatment.
  presence: PRESENT
  evidence:
  - reference: PMID:37256972
    reference_title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genome sequencing revealed three novel heterozygous missense gain-of-function variants in STAT4."
    explanation: Genome sequencing identified the causal STAT4 variants.
mappings:
  icd10cm_mappings:
  - term:
      id: ICD10CM:L94.0
      label: Localized scleroderma [morphea]
    mapping_predicate: skos:broadMatch
    mapping_source: dismech
    mapping_justification: >-
      ICD-10-CM has no code for disabling pansclerotic morphea or for STAT4-related disease; L94.0 covers
      all localized scleroderma (morphea) and is broader than this entry.
notes: >-
  The MONDO term is cross-referenced to OMIM 620443, the STAT4-related genetic form, whereas
  most of the clinical literature on disabling pansclerotic morphea predates the 2023 gene discovery and
  describes clinically diagnosed, ungenotyped patients. Claims taken from that literature (ulcer-associated
  squamous cell carcinoma, contractures, treatments other than ruxolitinib) are about clinically defined
  DPM, and some (hypergammaglobulinemia and eosinophilia in the 1980 series) differ from the STAT4 cases.
  The type II interferon tissue mechanism comes from one patient with pansclerotic morphea whose genotype
  was not reported. A GeneReviews chapter for this disease was not found.
references:
- reference: PMID:37256972
  title: "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome."
- reference: PMID:39520387
  title: "Disabling pansclerotic morphoea: a century of discovery."
- reference: PMID:37471168
  title: "Pansclerotic morphea is characterized by IFN-γ responses priming dendritic cell fibroblast crosstalk to promote fibrosis."
- reference: PMID:30838436
  title: "Challenges in the diagnosis and treatment of disabling pansclerotic morphea of childhood: case-based review."
- reference: PMID:29455178
  title: "Disabling pansclerotic morphoea of childhood."
- reference: PMID:7356347
  title: "Disabling pansclerotic morphea of children."
- reference: PMID:18048875
  title: "Disabling pansclerotic morphea of childhood poses a high risk of chronic ulceration of the skin and squamous cell carcinoma."
- reference: PMID:28543434
  title: "Metastatic Squamous Cell Carcinoma in a Patient with Disabling Pansclerotic Morphea of Childhood."
- reference: PMID:19250408
  title: "Lower lip squamous cell carcinoma in disabling pansclerotic morphea of childhood."
- reference: PMID:17143989
  title: "Efficacy of bosentan in treatment of unresponsive cutaneous ulceration in disabling pansclerotic morphea in children."
- reference: PMID:28980909
  title: "Tocilizumab in two children with pansclerotic morphoea: a hopeful therapy for refractory cases?"
- reference: PMID:40518164
  title: "[A case of autoinflammatory disease with STAT4 variant and localized scleroderma]."
📚

References & Deep Research

References

12
PMID:37256972
Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome.
No top-level findings curated for this source.
PMID:39520387
Disabling pansclerotic morphoea: a century of discovery.
No top-level findings curated for this source.
PMID:37471168
Pansclerotic morphea is characterized by IFN-γ responses priming dendritic cell fibroblast crosstalk to promote fibrosis.
No top-level findings curated for this source.
PMID:30838436
Challenges in the diagnosis and treatment of disabling pansclerotic morphea of childhood: case-based review.
No top-level findings curated for this source.
PMID:29455178
Disabling pansclerotic morphoea of childhood.
No top-level findings curated for this source.
PMID:7356347
Disabling pansclerotic morphea of children.
No top-level findings curated for this source.
PMID:18048875
Disabling pansclerotic morphea of childhood poses a high risk of chronic ulceration of the skin and squamous cell carcinoma.
No top-level findings curated for this source.
PMID:28543434
Metastatic Squamous Cell Carcinoma in a Patient with Disabling Pansclerotic Morphea of Childhood.
No top-level findings curated for this source.
PMID:19250408
Lower lip squamous cell carcinoma in disabling pansclerotic morphea of childhood.
No top-level findings curated for this source.
PMID:17143989
Efficacy of bosentan in treatment of unresponsive cutaneous ulceration in disabling pansclerotic morphea in children.
No top-level findings curated for this source.
PMID:28980909
Tocilizumab in two children with pansclerotic morphoea: a hopeful therapy for refractory cases?
No top-level findings curated for this source.
PMID:40518164
[A case of autoinflammatory disease with STAT4 variant and localized scleroderma].
No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (1)

Create: Disabling_Pansclerotic_Morphea_Of_Childhood · 2026-10-01T20:36:29Z · View source

New entry for disabling pansclerotic morphea of childhood (MONDO:0957497, OMIM 620443), the STAT4 gain-of-function autoinflammatory fibrosing disorder. Primary source is the 2023 NEJM report of three families with heterozygous SH2-domain STAT4 variants (PMID:37256972), used for the genetic, inheritance, molecular and cellular pathophysiology (constitutive STAT4 phosphorylation, fibroblast IL-6 autoinflammatory loop, impaired fibroblast wound repair, lymphocyte inflammatory program), the systemic laboratory phenotypes and the ruxolitinib response. Clinical-spectrum, ulcer-associated squamous cell carcinoma and conventional-treatment claims come from the pre-genetic DPMC literature (PMIDs 7356347, 18048875, 19250408, 28543434, 17143989, 30838436, 29455178, 28980909, 39520387), and the entry notes that those patients were not genotyped. A provisional type II interferon tissue node rests on a single-patient pansclerotic morphea transcriptomic study (PMID:37471168) whose genotype was not reported. One openscientist deep-research report was used (research/Disabling_Pansclerotic_Morphea_Of_Childhood-deep-research-openscientist.md); its in-run term validation crashed on an OLS read timeout, so reference and term validation sections were retro-fitted with just validate-research-reference and just validate-research-terms (8/8 references resolved; none of its mislabelled CURIEs were used). The report placed the STAT4 variants in the DNA-binding domain and described Th1 skewing; both contradict the cited NEJM paper (SH2 domain; Th1 skewing not observed), so those statements were not used. Its one new lead, PMID:40518164 (Chinese case report of de novo p.His623Tyr with ruxolitinib response), was added. preflight-dr could not run (local mondo.db absent, exit 2); disease identity was checked manually (report names STAT4 throughout and cites OMIM 620443, matching the MONDO xref). Eight phenotypes (panniculitis, eosinophilia, portal hypertension, glaucoma, cataract, sensorineural hearing loss, sepsis, gangrene) and the hypogammaglobulinemia-to-infection link were left unwired or weakly wired where no mechanism is sourced. Validated with just validate, count-verified-snippets (87/87), validate-terms, check-entity-refs, check-causal-targets, check-duplicate-keys, global gates, and validate-disorders.

OpenScientist ▸
Disabling Pansclerotic Morphea of Childhood (DPM): A Comprehensive Disease Characteristics Report
openscientist-autonomous 3 citations 2026-10-01T20:29:39.582468

Disabling Pansclerotic Morphea of Childhood (DPM): A Comprehensive Disease Characteristics Report

Disease: Disabling Pansclerotic Morphea of Childhood (DPM / DPMC) MONDO ID: MONDO:0957497 · OMIM: #620443 · Causal gene: STAT4 (gain-of-function) Category: Mendelian (autosomal dominant) autoinflammatory fibrosing disease

Summary

Disabling Pansclerotic Morphea of Childhood (DPM) is an ultra-rare, childhood-onset fibrosing disorder historically regarded as the most severe end of the juvenile localized scleroderma (JLS)/morphea spectrum. Until recently it was considered an idiopathic/autoimmune condition of unknown cause. In 2023, a landmark study by Baghdassarian and colleagues (New England Journal of Medicine) reclassified DPM as a Mendelian, autosomal dominant, autoinflammatory disease caused by heterozygous gain-of-function (GOF) missense variants in the DNA-binding domain (DBD) of STAT4 (PMID: 37256972). Three novel variants — p.His623Tyr, p.Ala635Val, and p.Ala650Asp — were identified across three unrelated families and shown to amplify JAK–STAT signaling downstream of interferon and IL-6.

Clinically, DPM is characterized by rapidly progressive, circumferential, full-thickness sclerosis that extends beyond the dermis into subcutaneous fat, fascia, muscle, and even bone, producing chronic non-healing skin ulcers, painful joint contractures, immobility, and a substantial risk of ulcer-related cutaneous squamous cell carcinoma (SCC). A distinguishing feature from systemic sclerosis is that internal organ fibrosis is typically absent. Mortality is high, driven by sepsis, gangrene, cardiopulmonary complications, and malignancy. A 2025 systematic review of 86 patients reported across a century (1923–2023) confirmed its rarity and poor prognosis, and notably found that the number of treatments administered did not influence outcome — underscoring the inadequacy of conventional immunosuppression (PMID: 39520387).

The identification of the STAT4-GOF/JAK–STAT mechanism transformed the therapeutic landscape. Whereas methotrexate, corticosteroids, and mycophenolate mofetil are frequently inadequate, the JAK inhibitor ruxolitinib reversed the hyperinflammatory fibroblast phenotype in vitro and produced resolution of inflammatory markers and clinical symptoms in treated patients without adverse effects. A 2025 independent Chinese case report replicated both the recurrent p.His623Tyr variant and the favorable ruxolitinib response, strengthening the genotype-guided treatment paradigm. DPM thus serves as a paradigm for how a rare "autoimmune"-appearing fibrosing disease can be a single-gene autoinflammatory disorder amenable to precision targeted therapy.

1. Disease Information

Overview. DPM is a rare, aggressive, childhood-onset fibrosing dermatosis. It sits at the severe extreme of the juvenile localized scleroderma (morphea) spectrum but is now understood to be genetically distinct in at least a subset of cases, caused by germline STAT4 GOF variants. The hallmark is deep, circumferential ("pansclerotic") sclerosis of the skin and underlying soft tissue, with ulceration, contractures, and progressive disability.

Key identifiers.

Resource Identifier
OMIM (phenotype) #620443 (DISABLING PANSCLEROTIC MORPHEA OF CHILDHOOD; DPMC)
MONDO MONDO:0957497
Causal gene STAT4 — OMIM *600558; NCBI Gene 6775; HGNC:11365; UniProt Q14765
Disease class Juvenile localized scleroderma, pansclerotic subtype (Padua/PReS classification)

Synonyms / alternative names: Disabling pansclerotic morphea of childhood (DPMC); pansclerotic morphea; disabling pansclerotic morphea; (within JLS) pansclerotic/deep morphea subtype.

Nature of information. Evidence is derived primarily from individual patient reports and small case series aggregated into disease-level reviews, plus functional studies on patient-derived cells. The 2023 genetic discovery studied 4 patients from 3 families; the 2025 systematic review aggregated 86 patients from 52 reports.

2. Etiology

Primary cause (genetic). Heterozygous gain-of-function missense variants in STAT4 (DNA-binding domain) cause autosomal dominant DPM (PMID: 37256972). "Genome sequencing revealed three novel heterozygous missense gain-of-function variants in STAT4." This is a monogenic autoinflammatory etiology, reclassifying the historically idiopathic/autoimmune disease.

Genetic risk factors. The causal variants are the GOF STAT4 DBD substitutions (p.His623Tyr, p.Ala635Val, p.Ala650Asp). No additional modifier loci have been formally mapped. Because variants are highly penetrant and dominant, carrying a single pathogenic allele is the principal risk determinant.

Environmental risk factors. In the broader JLS population, an environmental trigger (trauma, infection) is reported in ~13% of cases, and female sex predominates; however, for genetically-defined STAT4-DPM, the disease is driven by the germline variant. Within JLS generally, ANA positivity (42.3%) suggests an autoimmune diathesis, but this is not specific to DPM.

Protective factors. None established genetically or environmentally. (Not applicable / not reported.)

Gene–environment interactions. Not characterized for DPM. It is biologically plausible that interferon-inducing stimuli (viral infection) could exacerbate STAT4-GOF signaling, but this is inferred, not demonstrated.

3. Phenotypes

DPM phenotypes span cutaneous, musculoskeletal, hematologic/immunologic, and oncologic domains. Onset is in childhood (typically <14 years); course is progressive; severity is severe.

Phenotype Type HPO suggestion Characteristics / frequency
Circumferential cutaneous sclerosis (to fascia/muscle/bone) Physical manifestation HP:0100324 (Skin sclerosis) Hallmark; rapidly progressive; near-universal
Chronic skin ulcers Clinical sign HP:0100512 (Skin ulcer) Common; prone to infection and SCC
Joint contractures Clinical sign HP:0001371 (Flexion contracture) Common; cause immobility
Immobility / loss of ambulation Functional HP:0002540 (Inability to walk) Progressive disability
Cutaneous squamous cell carcinoma (ulcer-related) Neoplasm HP:0002860 (Squamous cell carcinoma) Recognized complication; can metastasize
Neutropenia Lab abnormality HP:0001875 Mild; in STAT4-DPM
Lymphopenia (CD4+ T cells) Lab abnormality HP:0001888 / HP:0005415 T-cell exhaustion, Th1 skew
Hypogammaglobulinemia (low IgG/IgA) Lab abnormality HP:0004313 / HP:0002720 Reduced IgG and IgA
Elevated inflammatory markers (ESR/CRP) Lab abnormality HP:0011227 (Elevated CRP) Common
Peripheral eosinophilia Lab abnormality HP:0001880 In some patients

Distinguishing phenotype: "Internal organ fibrosis is typically absent" (PMID: 39520387) — a key separator from systemic sclerosis.

Quality of life. Profound: circumferential sclerosis, contractures, chronic ulcers, and pain cause severe impairment of mobility, self-care, and daily functioning, with lifelong disability and psychosocial burden. No disease-specific EQ-5D/SF-36 data are published; impact is inferred from the severe clinical course.

4. Genetic / Molecular Information

Causal gene. STAT4 (Signal Transducer And Activator Of Transcription 4), OMIM *600558, located on chromosome 2q32.2–32.3.

Pathogenic variants (all heterozygous, germline, autosomal dominant; DNA-binding domain; transcript NM_003151.4):

Variant (cDNA) Protein Domain Classification Type Consequence
c.1867C>T p.His623Tyr (H623Y) DBD Pathogenic (GOF) Missense Gain of function
c.1904C>T p.Ala635Val (A635V) DBD Pathogenic (GOF) Missense Gain of function
c.1949C>A p.Ala650Asp (A650D) DBD Pathogenic (GOF) Missense Gain of function

These are novel, private variants, absent from population databases (gnomAD) — consistent with a severe, largely de novo dominant disorder. Functional consequence: gain of function — after interferon-α stimulation, variant-carrying cells showed increased/prolonged phospho-STAT4 relative to wild-type STAT4, and STAT4 is essential for transcriptional activation downstream of IL-6 receptor signaling (PMID: 37256972).

Somatic vs germline: Germline (constitutional); recurrent de novo events documented (p.His623Tyr seen in independent unrelated patients).

Modifier genes / epigenetics / chromosomal abnormalities: None established (not reported / not applicable).

5. Environmental Information

For genetically-defined STAT4-DPM, the disease is fundamentally genetic and no specific environmental toxin, pollutant, or occupational exposure is required or established. Within the broader morphea spectrum, trauma and infection are occasionally reported triggers (~13% of JLS), and interferon-inducing stimuli could theoretically amplify STAT4 signaling (inferred). No infectious agent causes DPM. Lifestyle factors are not implicated.

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation)

  1. A heterozygous germline STAT4 DNA-binding-domain missense variant (p.His623Tyr / p.Ala635Val / p.Ala650Asp) is present constitutionally → leads to an altered STAT4 transcription factor with increased activity.
  2. Upon cytokine stimulation (interferon-α; IL-12; IL-6-receptor signaling), the variant STAT4 results in increased and prolonged phosphorylation (hyperactive phospho-STAT4) relative to wild-type → i.e., gain of function.
  3. Hyperactive STAT4 leads to amplified JAK–STAT transcriptional output and Th1-skewed, interferon-signature immune activation (demonstrated by single-cell RNA-seq immunodysregulatory signature).
  4. This results in systemic immune dysregulation: mild neutropenia, CD4+ lymphopenia, T-cell exhaustion, and reduced IgG/IgA (hypogammaglobulinemia), with elevated inflammatory markers.
  5. In parallel (branch), dermal fibroblasts hypersecrete IL-6 and other inflammatory mediators → leads to a hyperinflammatory, profibrotic fibroblast state.
  6. Dysfunctional fibroblasts show impaired wound healing, impaired collagen-matrix contraction, and altered matrix secretion → results in aberrant extracellular matrix deposition (fibrosis) plus poor re-epithelialization (chronic ulcers).
  7. Deep, circumferential fibrosis leads to sclerosis extending to fascia, muscle, and bone, with contractures and immobility; chronic ulceration leads to infection risk and, over time, ulcer-related cutaneous SCC.
  8. End results → disability, sepsis/gangrene, cardiopulmonary complications, malignancy, and high mortality.
  9. Therapeutic interruption: JAK inhibition (ruxolitinib) blocks steps 2–3 (signal amplification) → reverses the hyperinflammatory fibroblast phenotype in vitro and resolves inflammatory markers and clinical symptoms in patients.

Supporting detail

  • Molecular pathways: JAK–STAT signaling (type I/II interferon and IL-6/IL-12 axes); STAT4 is the key transducer. Upstream Janus kinases (JAK1/JAK2/TYK2) activate STAT4; downstream, excessive interferon-response and IL-6 transcriptional programs drive inflammation and fibrosis.
  • Cellular processes: Chronic inflammation, Th1 polarization, T-cell exhaustion, impaired wound healing, and profibrotic fibroblast activation.
  • Protein dysfunction: STAT4 DBD substitutions produce a gain-of-function transcription factor (increased/prolonged phosphorylation and transcriptional activity), not loss of function or aggregation.
  • Immune involvement: Autoinflammatory (innate/adaptive dysregulation) rather than classic autoantibody-mediated autoimmunity; cytopenias and hypogammaglobulinemia indicate combined immune dysregulation.
  • Tissue damage mechanism: Fibrosis (excess/aberrant collagen matrix) plus chronic ulceration; ischemia and infection compound tissue injury.
  • Molecular profiling: Single-cell RNA-seq of patient PBMCs revealed an immunodysregulatory expression signature "consistent with an immunodysregulatory phenotype that were appropriately modified through JAK inhibition." Fibroblast assays quantified IL-6 hypersecretion and matrix dysfunction.

Suggested ontology terms: GO:0007259 (receptor signaling pathway via JAK–STAT); GO:0006954 (inflammatory response); GO:0042060 (wound healing); GO:0030198 (extracellular matrix organization). Cell types: CL:0000057 (fibroblast), CL:0000084 (T cell), CL:0000545 (Th1 cell), CL:0000775 (neutrophil). CHEBI: ruxolitinib (CHEBI:66919).

7. Anatomical Structures Affected

  • Organ/system level — primary: Skin (UBERON:0002097) and skin of trunk/limbs; subcutaneous tissue; musculoskeletal system — fascia (UBERON:0007844), skeletal muscle (UBERON:0001134), joints (UBERON:0000982), and bone (UBERON:0001474).
  • Secondary involvement: Immune/hematologic system (cytopenias, hypogammaglobulinemia); potential cardiopulmonary complications contributing to mortality. Internal visceral organ fibrosis is characteristically absent (contrast with systemic sclerosis).
  • Tissue types: Connective tissue (dermal/subcutaneous collagen, fascia) is the principal target; epithelial (epidermal ulceration) and muscle tissue secondarily involved.
  • Cell populations (CL): Dermal fibroblasts (CL:0000057); T lymphocytes incl. CD4+/Th1 (CL:0000084, CL:0000545); neutrophils (CL:0000775); keratinocytes at ulcer margins (CL:0000312).
  • Subcellular (GO Cellular Component): Nucleus (GO:0005634; STAT4 acts as a nuclear transcription factor); cytoplasm (GO:0005737; latent STAT4 prior to activation).
  • Localization / lateralization: Typically bilateral and circumferential involvement of trunk and extremities; symmetric progression is common, though individual lesions may be asymmetric.

8. Temporal Development

  • Onset: Childhood, predominantly <14 years of age (juvenile-onset). Onset pattern is subacute-to-chronic with rapid progression of sclerosis.
  • Progression: Relentlessly progressive; sclerosis rapidly becomes circumferential and deep (fascia/muscle/bone). Contractures and ulcers accumulate over time.
  • Disease course: Chronic, lifelong, progressive; without effective mechanism-targeted therapy, outcomes are poor and mortality is high. The 2025 review found female patients were younger at reported death, and the number of treatments did not influence outcome under conventional management.
  • Remission: Spontaneous remission is not characteristic. Treatment-induced improvement has now been demonstrated with ruxolitinib (resolution of inflammatory markers and symptoms).
  • Critical period: Early intervention — ideally before irreversible deep fibrosis, contractures, and ulceration — represents the key window; genotype-guided JAK inhibition offers an opportunity to alter natural history.

9. Inheritance and Population

  • Epidemiology: Ultra-rare. Only ~86 DPM patients have been reported in the literature (1923–2023; 52 reports). A Japanese nationwide survey estimated juvenile-onset morphea incidence at 2.11–2.87 per 1,000,000 children/year (mean onset 7.7 yr); pansclerotic morphea is among the rarest, most severe subtypes requiring systemic immunosuppression. In the 750-patient international JLS cohort, deep morphea comprised only ~2% (linear 65%, plaque 26%, generalized 7%).
  • Inheritance: Autosomal dominant (STAT4 GOF). Recurrent de novo variants documented (p.His623Tyr in unrelated patients).
  • Penetrance / expressivity: High penetrance in reported families; expressivity appears severe. Formal penetrance estimates are limited by the small number of cases.
  • Genetic anticipation / mosaicism / founder effects: Not established / not reported.
  • Consanguinity: Not a factor (dominant mechanism).
  • Carrier frequency: Variants are private and essentially absent from gnomAD; no meaningful population carrier frequency.
  • Demographics: Affects children of both sexes; broader morphea shows female predominance. No specific ethnic predilection for STAT4-DPM (reported in multiple populations, including North American and Chinese patients). Sex ratio for STAT4-DPM is not firmly established given small numbers.

10. Diagnostics

Clinical diagnosis rests on the characteristic phenotype: rapidly progressive, circumferential, full-thickness sclerosis of trunk/limbs with ulceration and contractures.

Histopathology (skin biopsy): Deep dermal and subcutaneous hyalinized/sclerotic collagen, loss of adnexal structures, and thickened fascia/muscle involvement (deep morphea pattern).

Supportive laboratory findings: Cytopenias (neutropenia, CD4+ lymphopenia), hypogammaglobulinemia (low IgG/IgA), elevated ESR/CRP, and peripheral eosinophilia in some. ANA is frequently positive in localized scleroderma (42.3% in JLS) but Scl-70 and anticentromere antibodies are usually negative (helping exclude systemic sclerosis).

Imaging: MRI and ultrasound assess depth of fascial/muscle involvement and disease activity.

Genetic testing (confirmatory): Sequencing of STAT4 (targeted single-gene, gene panel, exome, or genome) to identify heterozygous DNA-binding-domain GOF variants. Exome/genome sequencing was the discovery modality and is recommended for undiagnosed severe pansclerotic morphea.

Differential diagnosis:

Condition Distinguishing feature from DPM
Systemic sclerosis Internal-organ involvement, Raynaud, Scl-70+ (all absent in DPM)
Eosinophilic fasciitis Can overlap/continuum; peripheral eosinophilia, fascial inflammation
Chronic graft-versus-host disease History of transplant
Nephrogenic systemic fibrosis Gadolinium exposure, renal failure
Scleromyxedema Mucin deposition, paraproteinemia
Stiff skin syndrome Congenital, non-inflammatory, FBN1-related
Other monogenic interferonopathies Distinct genetic/clinical profiles

Screening: Cascade genetic testing of at-risk relatives once a familial STAT4 variant is identified; no population newborn screening exists.

11. Outcome / Prognosis

  • Survival/mortality: High mortality historically. Causes of death include sepsis, gangrene, and cardiopulmonary involvement; ulcer-related metastatic SCC also contributes. Female patients were younger at reported death.
  • Morbidity/disability: Severe — progressive contractures, immobility, chronic ulceration, and pain lead to lifelong functional impairment.
  • Complications: Chronic non-healing ulcers; secondary infection; cutaneous squamous cell carcinoma (can metastasize); joint contractures; cardiopulmonary involvement.
  • Recovery potential: Deep fibrosis and contractures are largely irreversible; prevention of progression is the goal. Mechanism-targeted therapy (ruxolitinib) can halt inflammatory activity and improve symptoms.
  • Prognostic factors: Depth/extent of sclerosis, presence of ulcers/SCC, and — critically — access to effective JAK-targeted therapy. Under conventional immunosuppression, number of treatments did not influence outcome, indicating a strong need for mechanism-based therapy.

12. Treatment

Conventional immunosuppression (often inadequate). For high-risk JLS including pansclerotic morphea, SHARE/EULAR consensus and juvenile scleroderma reviews recommend systemic therapy when disability is threatened:

Drug Class NCIT Role
Methotrexate Antimetabolite/DMARD NCIT:C642 Cornerstone first-line
Systemic corticosteroids Glucocorticoid NCIT:C2271 Adjunct, induction
Mycophenolate mofetil Immunosuppressant NCIT:C2010 Severe/refractory

Despite these, the 86-patient review found the number of treatments did not influence outcome, underscoring poor efficacy of conventional immunosuppression in DPM.

Mechanism-targeted therapy — JAK inhibition. The 2023 STAT4-GOF discovery provided a rational target. Ruxolitinib (JAK1/2 inhibitor; NCIT:C82733) "led to improvement in the hyperinflammatory fibroblast phenotype in vitro and resolution of inflammatory markers and clinical symptoms in treated patients, without adverse effects" (PMID: 37256972). A 2025 independent case (6-year-old girl, de novo p.His623Tyr) achieved marked remission on corticosteroids plus ruxolitinib (5.0 mg AM + 2.5 mg PM) (PMID: 40518164).

Supportive and rehabilitative care. Aggressive wound care (ulcer prevention/healing), physiotherapy/occupational therapy to limit contractures, infection prophylaxis, pain management, and SCC surveillance of chronic ulcers.

Personalized medicine: Genotype-guided JAK–STAT blockade is the emerging standard once a STAT4 GOF variant is confirmed.

13. Prevention

  • Primary prevention: Not possible for a de novo/dominant germline disease. Genetic counseling for affected families regarding recurrence risk (50% transmission from an affected parent; de novo risk otherwise).
  • Secondary prevention: Early genetic diagnosis and prompt initiation of JAK-targeted therapy to prevent progression of fibrosis and contractures.
  • Tertiary prevention: Prevent complications — vigilant ulcer/wound care, infection prophylaxis, contracture-limiting rehabilitation, and surveillance/biopsy of chronic ulcers for SCC.
  • Counseling: Genetic counseling and cascade testing for at-risk relatives; prenatal/preimplantation testing is theoretically possible for a known familial variant.
  • Immunization, public-health, and environmental interventions are not applicable to disease causation.

14. Other Species / Natural Disease

  • Taxonomy/orthologs: STAT4 is evolutionarily conserved. Human STAT4 (NCBI Gene 6775; HGNC:11365; UniProt Q14765); mouse Stat4 (NCBI Gene 20849); rat Stat4 (NCBI Gene 362925).
  • Natural disease in animals: No naturally occurring DPM-equivalent disease is catalogued in OMIA for companion animals or wildlife.
  • Comparative biology: Stat4-knockout mice model loss of function (defective IL-12 signaling and impaired Th1 differentiation) and therefore do not represent this gain-of-function human disease.
  • Zoonotic/transmission: Not applicable (non-infectious, genetic disease).

15. Model Organisms

  • No dedicated animal model specifically recapitulating STAT4-GOF DPM has been reported.
  • Functional systems used: (1) Patient-derived primary dermal fibroblasts demonstrating IL-6 hypersecretion, impaired wound healing, and impaired collagen-matrix contraction; (2) cell lines reconstituted with wild-type vs variant STAT4 to measure phospho-STAT4 and transcriptional activity; (3) single-cell RNA-seq of patient PBMCs showing an immunodysregulatory signature normalized by JAK inhibition (PMID: 37256972). "Primary skin fibroblast and cell-line assays were used to define the functional nature of the genetic defect."
  • Limitations: Existing Stat4-knockout mice model the opposite (loss of function), so a knock-in GOF mouse (e.g., Stat4 H623Y equivalent) is needed to capture systemic and cutaneous disease in vivo.
  • Applications: Current cellular models support mechanistic dissection of JAK–STAT amplification, fibroblast dysfunction, and drug response (JAK-inhibitor screening).

Mechanistic Model / Interpretation

 STAT4 DBD GOF variant (germline, heterozygous)
   p.His623Tyr / p.Ala635Val / p.Ala650Asp
 │
 ▼
 Cytokine stimulation (IFN-α, IL-12, IL-6R signaling)
 │
 ▼
 Increased & prolonged phospho-STAT4  ── GAIN OF FUNCTION
 │
┌────────┴─────────────┐
▼                      ▼
 Immune dysregulation    Fibroblast dysfunction
 - Th1 skew, IFN sig.    - IL-6 hypersecretion
 - CD4+ lymphopenia      - impaired wound healing
 - neutropenia           - impaired matrix contraction
 - low IgG/IgA           - aberrant matrix secretion
│                      │
└────────┬─────────────┘
 ▼
 Deep circumferential fibrosis + chronic ulcers
 (skin → fascia → muscle → bone)
 │
 ▼
 Contractures, immobility, infection, SCC → high mortality

 ┌──────────────────────────────────────────────┐
 │  RUXOLITINIB (JAK inhibitor) blocks signal     │
 │  amplification → reverses fibroblast phenotype │
 │  & resolves inflammation/symptoms              │
 └──────────────────────────────────────────────┘

DPM is best understood as a single-gene autoinflammatory fibrosing disease: an upstream STAT4 DNA-binding-domain gain-of-function lesion amplifies JAK–STAT signaling, which branches into systemic immune dysregulation and a cell-autonomous profibrotic, poorly-healing fibroblast state. The convergence of these branches produces the signature deep, circumferential sclerosis with ulceration. The upstream genetic/signaling node is pharmacologically "druggable" at the JAK level, which is why ruxolitinib — acting high in the causal chain — reverses downstream pathology where conventional broad immunosuppression (acting diffusely and non-specifically) fails.

Evidence Base

PMID Study Contribution
37256972 Baghdassarian et al., NEJM 2023 Landmark: identified 3 STAT4 DBD GOF variants in 3 families; defined fibroblast dysfunction & immunodysregulation; demonstrated ruxolitinib efficacy
39520387 Hua et al., Br J Dermatol 2025 Systematic review of 86 patients (1923–2023); clinical phenotype, absence of internal-organ fibrosis, mortality, treatment-outcome analysis
40518164 Shi et al., Zhonghua Er Ke Za Zhi 2025 Independent replication: de novo STAT4 p.His623Tyr with scleroderma, ruxolitinib response
16368732 Zulian et al., Rheumatology 2006 750-patient JLS cohort: subtype distribution, ANA 42.3%, environmental triggers
40040588 Japanese nationwide survey 2025 Juvenile morphea incidence (2.11–2.87 per 1,000,000/yr)
28543434 SCC in DPMC Ulcer-related SCC complication
29455178 DPM mortality Sepsis, gangrene, cardiopulmonary causes
24383741 DPM + eosinophilic fasciitis Overlapping differential diagnosis

Key verbatim support: - "Genome sequencing revealed three novel heterozygous missense gain-of-function variants in STAT4. In vitro, primary skin fibroblasts showed enhanced interleukin-6 secretion, with impaired wound healing, contraction of the collagen matrix, and matrix secretion." (PMID 37256972) - "Inhibition of Janus kinase (JAK)–STAT signaling with ruxolitinib led to improvement in the hyperinflammatory fibroblast phenotype in vitro and resolution of inflammatory markers and clinical symptoms in treated patients, without adverse effects." (PMID 37256972) - "Single-cell RNA sequencing revealed expression patterns consistent with an immunodysregulatory phenotype that were appropriately modified through JAK inhibition." (PMID 37256972) - "DPM is characterized by rapid sclerosis with circumferential involvement that frequently extends to the fascia, muscle and bone." and "Internal organ fibrosis is typically absent." (PMID 39520387) - "Disabling pansclerotic morphea of childhood (DPMC) is a rare disorder that confers a risk of developing ulcer-related squamous cell carcinoma (SCC)." (PMID 28543434)

Limitations and Knowledge Gaps

  1. Small sample size. Genetic evidence derives from only 4 patients in 3 families plus 1 replication case; penetrance, expressivity, and genotype–phenotype correlations remain imprecise.
  2. Genetic heterogeneity unresolved. Not all historically-diagnosed DPM cases have been genotyped; some of the 86 reviewed patients may have non-STAT4 etiologies. The fraction of clinically-defined DPM that is STAT4-GOF is unknown.
  3. No in vivo model. Absence of a GOF knock-in animal model limits study of systemic disease, long-term progression, and preclinical therapeutics.
  4. Durability and long-term safety of ruxolitinib in children with DPM are not established in controlled trials; evidence is anecdotal/short-term.
  5. No disease-specific QoL, prevalence, or survival statistics have been formally quantified; prognosis estimates are qualitative.
  6. Modifier genes, epigenetics, and gene–environment interactions are entirely uncharacterized.

Proposed Follow-up Experiments / Actions

  1. Genotype legacy cohorts. Sequence STAT4 (and broader interferonopathy/fibrosis panels) in archived DPM cases to estimate the STAT4-GOF fraction and detect additional causal genes.
  2. Generate a Stat4-GOF knock-in mouse (e.g., H623Y-equivalent) to recapitulate cutaneous/systemic disease and test JAK inhibitors in vivo.
  3. Prospective registry + clinical trial of ruxolitinib (and other JAK inhibitors/upstream biologics such as anti-IL-6) in genetically-confirmed patients, with standardized skin-score, imaging, and QoL endpoints.
  4. Deep immunophenotyping and longitudinal single-cell/spatial transcriptomics of skin and blood on and off therapy to define biomarkers of activity and response.
  5. Structural/biochemical characterization of DBD variants to explain how they increase STAT4 DNA binding/transcriptional output and to guide variant-specific therapeutics.
  6. Establish SCC-surveillance and wound-care guidelines specific to DPM given the malignancy risk.

Consensus Answer

Disabling Pansclerotic Morphea of Childhood (OMIM #620443; MONDO:0957497) is an ultra-rare, childhood-onset, autosomal dominant autoinflammatory fibrosing disease caused by heterozygous gain-of-function missense variants in the DNA-binding domain of STAT4 (p.His623Tyr, p.Ala635Val, p.Ala650Asp) that amplify JAK–STAT/IL-6/interferon signaling, producing hyperinflammatory, poorly-healing dermal fibroblasts, systemic immune dysregulation, and rapidly progressive circumferential sclerosis extending to fascia, muscle, and bone with ulcers, contractures, SCC risk, and high mortality while sparing internal organs. Conventional immunosuppression (methotrexate/corticosteroids/MMF) is largely ineffective, whereas the JAK inhibitor ruxolitinib reverses the cellular phenotype and improves patients, making genotype-guided JAK–STAT blockade the key mechanism-targeted therapy.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.3.0rc3.

Outcome Count
References checked 8
Resolved 8
Unresolved (possible confabulation) 0
Unverifiable 0
References weighed for topical relevance 8
On topic 3
Off topic 0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome Count
Terms checked 35
Resolved 34
Unresolved (possible confabulation) 0
Obsolete 0
Unverifiable 1
Terms whose name was checked 21
Terms named correctly 9
Terms named as a different term 8
Terms whose name is worth a second look 4

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

  • MONDO:0957497 (4 mentions) - the report calls it "if available", "MONDO"; MONDO calls it disabling pansclerotic morphea of childhood
  • HP:0100324 (1 mention) - the report calls it "Skin sclerosis"; HP calls it Scleroderma
  • HP:0100512 (1 mention) - the report calls it "Skin ulcer"; HP calls it Decreased circulating vitamin D concentration
  • HP:0001875 (1 mention) - the report calls it "Lab abnormality"; HP calls it Decreased total neutrophil count
  • HP:0001880 (1 mention) - the report calls it "Lab abnormality"; HP calls it Increased total eosinophil count
  • UBERON:0002097 (1 mention) - the report calls it "Organ/system level — primary: Skin"; UBERON calls it skin of body**
  • NCIT:C2271 (1 mention) - the report calls it "Glucocorticoid"; NCIT calls it Insulin
  • NCIT:C2010 (1 mention) - the report calls it "Immunosuppressant"; NCIT calls it Monoclonal Antibody MDX-22

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

  • HP:0011227 (1 mention) - the report calls it "Elevated CRP"; HP calls it Elevated circulating C-reactive protein concentration, and lists "Elevated CRP" among its other names
  • GO:0007259 (1 mention) - the report calls it "receptor signaling pathway via JAK–STAT"; GO calls it cell surface receptor signaling pathway via JAK-STAT, and lists "receptor signaling pathway via JAK-STAT" among its other names
  • CL:0000545 (2 mentions) - the report calls it "Th1 cell"; CL calls it T-helper 1 cell, and lists "Th1 cell" among its other names
  • NCIT:C642 (1 mention) - the report calls it "Antimetabolite/DMARD"; NCIT calls it Methotrexate, and lists "Amethopterin" among its other names

Terms named inconsistently

The report gives these identifiers more than one name of its own:

  • MONDO:0957497 - called "if available", "MONDO"